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n 1897 Josef Conrad wrote that an author must be like an artist in capturing the movement of a 
dart into stone or the magic intonation into a piece of music. In the same manner a scientist 
must use artistic abilities to grasp the complexity of his work and to interpret its content. But in 
contrast to the artist who works with ideas the scientist follows the path of facts.  
Within this context the author, artist and scientist behind this work will take the 
reader on a journey through the development of drug eluting hydrogels and put those in the context 



























ydrogels have successfully proved themselves useful for drug delivery applications and 
several delivery routes have been developed over the years. The particular interest in this 
work was to design, synthesise and evaluate in situ forming drug eluting hydrogels, which have the 
potential to ameliorate the healing of cardiovascular diseases. 
With this aim the anti-inflammatory and immunosuppressant drugs rapamycin (Ra) 
and dexamethasone (Dex) were made water soluble by conjugation with polyethylene glycol (PEG). 
Ra was attached pendant from the terminal of PEGs while Dex was incorporated into dendritic 
structures grown from PEGs. These conjugates were further crosslinked into hydrogels by either 
conjugate or thiol-ene addition. The gel degradation was tuned to take between 5 and 27 days by 
using gel building block combinations that induced either 2 or 4 hydrolytically labile bonds per 
crosslink or by varying the number of crosslinking sites of the building blocks. The use of thiol-ene 
addition prolonged the degradation time nearly seven folded compared to conjugate addition as a 
more stable crosslink was formed. 
 Two different formulations for gelling via conjugate addition were used (acrylate-thiol 
or vinyl sulphone-thiol) to deliver Ra, which was carried by either a 4- or 2-armed PEG. The elution 
kinetic for the respective gel formulation was of zero order during 15 and 19 days of gel degradation. 
In addition, Ra was PEGylated via esters, with a distance of either one or two carbons to a nearby 
thio-ether functionality. The difference in ester conjugation resulted in a slight but significant change 
in drug-PEG conjugate stability, which was mirrored by the increased time to reach the half amount 
of total drug elution; from 9.3 to 10.2 days and from 5.1 to 9.7 days for the two gel formulations, 
respectively. Dexamethasone was incorporated via an ester into dendrons of first and second 
generation pending from 2- and 4-armed PEGs at loadings of 2, 4 or 6 Dex molecules per carrier 
molecule. The resulting elution kinetic was of zero order during degradation periods of 5-27 days. 
Released Dex still possessed biological activity as determined by an in vitro cell assay. 
 
The novelties in this thesis are: (A) slow release of rapamycin obtained by covalent incorporation into 
hydrogels, (B) the use of unique PEG-based dendrimers to incorporate dexamethasone into a 



























ydrogeler har framgångsrikt visat sig användbara för att leverera läkemedel och ett flertal 
metoder har utvecklats de senaste 20 åren. Fokuset i den här avhandlingen ligger på att 
designa, framställa och utvärdera läkemedelsutsöndrande hydrogeler som spontanhärdar in situ, 
vilka har potential att förbättra läkningen efter kardiovaskulär sjukdom.  
 Med det syftet gjordes de anti-inflammatoriska och immunsänkande läkemedlen 
rapamycin (Ra) och dexametason (Dex) vattenlösliga genom att konjugeras med polyetylenglygol 
(PEG). Ra fästes kovalent längst ut på PEGar medans Dex inkluderades i dendritiska strukturer vilka 
byggdes från ändpunkten av PEGar. De här konjugaten tvärbands till hydrogeler via antingen 
konjugerad addition eller radikal polymerisation. Nedbrytningen av gelerna trimmades till att ta 
mellan 5 och 27 dagar genom att använda kombinationer av gelbyggstenar som bildar antingen 2 
eller 4 hydrolyserbara estrar per tvärbindning eller genom att variera antalet tvärbindningspunkter 
hos byggstenarna. Användandet av radikal polymerisation i sig ledde till att nedbrytningen av geler 
tog nära sju gånger längre tid jämfört med geler gjorda via konjugerad addition eftersom stabilare 
tvärbindningar då formas. 
 Två olika kombinationer för härdning via konjugerad addition (akryl-tiol eller 
vinylsulfon-tiol) användes för att leverera Ra som bars av antingen en 4- eller 2-armad PEG. 
Utsöndringskinetiken av Ra för de två kombinationerna var av nollte ordningen under de 15 och 19 
dagar som gelerna degraderade. Dessutom, Ra PEGylerades via estrar med ett avstånd på antingen 
ett eller två kol till en närliggande tioeter. Skillnaden i avstånd ledde till en liten men signifikant 
skillnad i stabiliteten hos Ra-PEG konjugaten, vilket speglades i den förlängda tiden att nå halva 
mängden av den totala läkemedelsutsöndringen; från 9.3 till 10.2 dagar och från 5.1 till 9.7 dagar för 
de två respektive gelkombinationerna. Dex kopplades in via en esterbindning till dendroner av första 
och andra generationen byggda från PEGar med 2 eller 4 armar, vilket resulterade i att 2, 4 eller 6 
Dex levererades per bärarmolekyl. Dex eluerade med nollte ordningens kinetik under 
degraderingsperioder på mellan 5 och 27 dagar. Vidbehålllen biologisk aktivitet av eluerad Dex 
bekräftades genom cellexperiment in vitro. 
 
Nyheterna i den här avhandlingen består av: (A) kontrollerad utsöndring av rapamycin uppnådd 
genom kovalent inbindning till hydrogeler, (B) användandet av unika PEGbaserade dendrimerer för 
kovalent inbindning av dexametason till hydrogeler och (C) nollte ordningens utsöndring av 
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1   INTRODUCTION 
 
ver the last century the concept of hydrogels has been developed into an interesting branch 
of polymer science with enormous potential. Particularly fruitful is the use of hydrogels in 
medical research where gels are commonly used in a wide spectrum of applications. There are 
multiple parameters to consider in the design of a hydrogel, which must all individually be adapted to 
obtain desired gel properties. This broad register of choices is the origin of the success for hydrogel 
applications, since it allows for the preparation of gels with very divert but specific properties. Hence, 
with proper design and methodology it is possible to create gels that fulfil the strict demands of a 
biomaterial (Hoffman 2002) which can be used as wound covers, implant coatings, slow-release 
devices or materials that mimic in vivo functionality (Hubbell 1998; Lin et al. 2009). Commonly, drugs 
or growth factors are delivered with the hydrogels to obtain these properties in a biological system. 
 Many drugs however, are hydrophobic and therefore insoluble in the human aqueous 
media, which is a problem for drug delivery and efficiency. The non-solubility is a particular problem 
in cases where the drug is delivered from a solution, as only aqueous solutions should be introduced 
into living tissue. Therefore various approaches towards in situ delivery of hydrophobic drugs have 
been developed and a common method is to conjugate the drug to a water soluble polymer, such as 
PEG (polyethylene glycol). This conjugation does not only bring the drug into solution but also 
increases its circulation time and protects it, primarily in case of peptides and proteins, against 
proteolytic activity (Woghiren et al. 1993; Gombotz et al. 1995; Elbert et al. 2001; Roberts et al. 
2002; Li et al. 2003; Frokjaer et al. 2005; Veronese et al. 2005). 
 
Rapamycin (McMurray et al.), a macrolide compound originally developed as an antifungal agent, 
and Dexamethasone (Dex), a synthetic member of the glucocorticoid class of steroid drugs, both 
have immunosuppressant and anti-inflammatory properties. These drugs have high potential for 
ameliorating cardiovascular healing, which is of interest to our group, and have previously been used 
to prevent restenosis (Morice et al. 2002; Koenig et al. 2009), quench pathological cardiac 
hypertrophy (McMullen et al. 2004) and to reduce inflammation from implanted devices (Baeyens et 
al. 1998). 
 
One approach to ameliorate cardiovascular recovery is by means of drugs and a crucial step in such 
approach is to develop suitable drug delivery devices. This thesis describes the development of 
methods to obtain controlled and sustained drug delivery of Ra and Dex via hydrogels and is part of a 




















other gel formulations than described here). The methods are based on drug PEGylation and the 
work shows the importance of proper design of the hydrogel formulation and drug incorporation 
methods to achieve desired properties. 
 
1.1   Hydrogels 
A hydrogel is formed by creating a sufficient number of crosslinks between polymeric building blocks 
so that a continuous three-dimensional (3D) network is created. The most representative feature of 
hydrogels is the ability to absorb large amounts of water. 
In theory a multi-arm with only two functional groups (fa =2) could be crosslinked by a 
2-armed crosslinker (fb =2), but then the hydrogel would not consist of an inter-crosslinked polymer 
network but a random entanglement of copolymers, which demands a conversion of 100% to form 
according to Equation 1. Practically however, a functionality of three is the minimum requirement 
for the multi-arm to form an infinitely connected network when crosslinked by a 2-armed crosslinker 
and according to Equation 1 a conversion of 71% is needed for this combination to reach the gel 
point. 
 
Critical conversion    (1) 
 
The final degree of conversion is individual for each hydrogel system and increased by high polymer 
concentration and long gelling time (DuBose et al. 2005). 
 
Figure 1 illustrates the resulting continuous network after crosslinking an 8-armed star shaped multi-
arm with a 2-armed linear crosslinker. A stoichiometric ratio (1:1) for the functional groups of the 
two pregel components is fundamental for the gel to form. Only a few percent deviations may 
prevent the gelling, or at least drastically slow down the process. In the case where too many of the 
multi-arms are present mainly dimers are formed while an excess of crosslinker saturates the multi-
arm and hence, no continuous network is formed. Nonetheless, even for a stoichiometric relation the 
crosslink efficiency is not 100% since the progressing network formation itself makes the forming gel 
more rigid, which lowers the possibility for remaining functional groups to come in close enough 


























Figure 1: A continuous polymer network formed by crosslinking an 8-armed star shaped 
multi-arm with a 2-armed linear crosslinker. 
 
One approach to categorise hydrogels is by their building blocks and a major distinction is usually 
made between natural and synthetic polymers, some of which are listed in Table 1 (Gombotz et al. 
1995; Hoffman 2002). Many of the naturally occurring polymers contain charged groups, signalling 
peptides or other functionalities, which make them useful for many applications but also 
unpredictable since different polymer sources may vary in the substitution pattern. Synthetic 
polymers on the other hand have greater potential to be tailored into desired properties with good 
repeatability. 
 
Table 1: Common naturally occurring and synthetic building blocks used for hydrogel 
assembling. 









poly(acrylic acid), PAA 
poly(ethylene glycol), PEG 
poly(glycolic acid), PGA 
poly(lactic acid), PLA 
poly(lactic-co-glycolic acid), PLGA 
poly(N-isopropyl acrylamide), PNIPAAm 
poly(N-vinyl-2-pyrrolidone), PVP 
poly(vinyl alcohol), PVA 
 
When hydrogels are required for in vivo use, biocompatibility is crucial. A biocompatible material 
should be inert to proteins and other substances in biological fluids as well as to receptors and other 
parts of cell membranes (Lee et al. 2000). Materials made of PLGA are hydrophobic, and in contact 














(Miller et al. 2005). This protein layer possesses an intrinsic cell adhesive property, which might be 
the reason why hydrophobic polymers are more prone to initiate an inflammatory response than 
hydrophilic polymers. A general method to decrease the hydrophobicity and simultaneously increase 
backbone flexibility of PLA, PGA and PLGA polyesters is to incorporate them in block copolymers with 
PEG. These block copolymers and devices made thereof are degradable since the polyesters degrade 
by hydrolysis, and in addition enzymatically in vivo (Reeve et al. 1994). Even though these polyesters 
are hydrophobic, there is a widespread use of the PEG copolymers for the preparation of hydrogels 
(Qiao et al. 2005), micro/nano particles (Gombotz et al. 1995) and micelles (Song et al. 2011) in 
applications where degradability is essential. 
 In contrast, polymer coatings of the hydrophilic polymer PEG is known to increase 
platelet and bacterial repellence on implants and is thus a suitable material for biomedical 
applications (Lee et al. 2000). PEG hydrogels are also extremely non-adhesive towards blood proteins 
and cells and are approved by the Food and Drug Administration in the United States for various 
clinical uses such as biosensors, valves and surface mono layers in microarray devices (Peppas et al. 
2006). In vivo, a degrading PEG material is slowly dissolved into the circulatory system and further 
cleared via both renal and hepatic pathways (Veronese et al. 2005). The “bio-inert” property of PEG-
based gels can be explained by its extensive interaction with water (a typical hydrogel absorbs water 
until it contains only ~1-10% dry material), which acts like a camouflage for the immune system. A 
wide range of hydrophilic synthetic polymers have been thus used to create hydrogels for medical 
applications (Hoffman 2002). 
 
Up to this point, the origin and some of the intrinsic properties of the polymeric building blocks used 
to assemble hydrogels have been presented. However, to obtain desired gel properties the geometry 
of the building blocks is as important as the polymer properties itself. The geometry determines the 
general gel properties, such as swelling (DuBose et al. 2005), mechanical strength (Anseth et al. 
1996) and drug diffusion properties (van de Wetering et al. 2005). Polymer geometries which are 
often used include linear, star shaped and dendritic structures. In Figure 2 a linear polymer is shown 
with the functional groups pending along its backbone. It is noticeable that this structure carries only 
one kind of functionality, consequently drug incorporation and hydrogel network formation must 
occur via the same chemistry, often simultaneously in a one-pot reaction. Also shown is a 4-armed 
star shaped dendritic structure of second generation. The dendrimer carries two different 
functionalities of orthogonal character (i.e. one can be reacted specifically without affecting the 
other). Therefore drug attachment is carried out in a separate reaction step prior gel formation, 
























Figure 2: Examples of two PEG architectures; to the left a linear backbone with pending 
functional groups and to the right a 4-armed PEG dendrimer of second generation. 
 
Dendritic materials have excellent intrinsic properties for drug delivery purposes and have 
successfully proved their usefulness in a number of delivery routes (Cheng et al. 2008). The specific 
advantages of dendritic structures compared to multi-arm polymers are the increased multivalency 
and the possibility of making them bi-functional. Recent developments of dendritic structures allow 
for a higher number of functional groups in fewer synthetic steps (Antoni et al. 2009), which for drug 
delivery purposes can be used to obtain high drug loading densities. An example of such material is 
the 2-Amino-2-hydroxymethyl-propane-1,3-diol (trizma) based dendrimer of third generation, 
synthesised by Antoni et al. in 6 steps, with 24 functional A groups and 21 B groups, where A and B 
are orthogonal. For dendritic materials in drug delivery applications functionality A is used to 
incorporate the drug while B is conjugated to tissue targeting molecules, polymers to increase water 
solubility or used for crosslinking to form a hydrogel (Ihre et al. 2002; Cheng et al. 2008). Even though 
dendritic materials have shown low cytotoxicity (Padilla De Jesus et al. 2002; Antoni et al. 2009) 
these carriers tend to accumulate in various organs within a few hours after intravenous 
administration. However, both the biodistribution and the retention time are improved by 
dendrimers PEGylation (Cheng et al. 2008). 
 
The hydrogel scaffolds used in this thesis were constructed from PEG building blocks of several 
geometries. One approach used mono-functional 2- or 4-armed PEGs with terminal functional groups 
used for both drug incorporating and crosslinking. Alternatively, dendritic 2- or 4-armed bi-functional 






























Figure 3: The geometries used for the work in this thesis. Top structures; 2- and 4-armed 
mono-functional PEGs. Lower structures; 2- and 4-armed dendritic PEGs of first generation 
followed by a 2-armed dendritic PEG of second generation. 
 
1.1.1   Gelling Methods 
Gelling occurs by establishing several crosslinks between the participating polymeric building blocks. 
The connections could be of either non-covalent character (electrostatic or solvent induced) as for 
“physical hydrogels” or covalent bonds, making “chemical hydrogels”. 
 
1.1.1.1   Physical Gels 
For physical gels the polymer is either functionalised by charged groups, which are crosslinked by 
species of the opposite charge, or made of blocks that associate to minimise the contact with the 
surrounding media. Physical gels could also form from hydrogen bonding of functional groups along 
the backbone of the polymer. For example, a solution of alginate (a brown algae polysaccharide 
highly substituted with anionic carboxylic acid groups) gels upon addition of cationic polymers like 











































Figure 4: Formation of a physical hydrogel from alginate by crosslinking with either charged 
polymers or ions. 
 
A potential niche of physical hydrogels is polymer-clay composite gels where clay particles are used 
as crosslinkers in free radical polymerisation of monomers. Those composites have shown 
extraordinary mechanical properties such as a 3 300 times higher fracture energy than conventional 
chemically crosslinked hydrogels (Haraguchi 2007). 
 
1.1.1.2   Chemical Gels 
In contrast to physical gels, polymers used to form a chemical gel carry functional groups which react 
by free radical reactions, or with a crosslinker carrying complementary functionality, to form covalent 
bonds (Hennink et al. 2002). Chemical gels have the advantage over conventional physical gels of 
being both stronger and more easily tailored to obtain desired properties, while physical gels benefit 
from their reversibility. 
 
The work in this thesis is based on chemical gels formed by free radical polymerisation reactions or 
conjugate addition between PEG multi-arms carrying acrylate or thiol functionalities. 
 
1.1.1.2.1   Photo-Polymerisation 
Gelling through photo-polymerisation occurs when polymers containing olefinic groups are exposed 
to radicals, most commonly initiated by heat or ultraviolet (Sen et al.) irradiation. The resulting 
crosslinks are of carbon-carbon character (Srinivasan et al. 2010), which are considered non-











































1.1.1.2.2   Thiol-ene Addition 
To introduce covalent crosslinks other than carbon-carbon bonds during free radical polymerisation 
the concept of thiol-ene chemistry may be used. In this concept the propagating radical is formed on 
a thiol species which then reacts with the “ene” (double bond). Scheme 1 pictures the general 
mechanism of the thiol-ene addition reaction. In the initiation step a photo initiator (I) is activated to 














Scheme 1: General thiol-ene reaction mechanisms for allyl-thiol and acrylate-thiol systems, 
respectively. Red colour indicates bonds formed during thiol-ene addition. 
 
Most often the olefin in thiol-ene reactions is an allyl, but in this thesis acrylates were used instead. 
Therefore the propagation and chain transfer steps of both groups are shown. In the propagation 
step the initially formed thiyl radical combines with the double bond to form a new bond, marked in 
red, while transferring the radical into the former double bond. The following reaction step is crucial 
for the gel properties (explained later) since the radical could react either via chain transfer by 
abstracting the hydrogen from a thiol or via homo-polymerisation to form a dimer. For a 
stoichiometric thiol-acrylate system the chain transfer step is slow compared to the propagation step 
(Cramer et al. 2003), hence the acrylate radical intermediate is rather stable and has the opportunity 
to undergo both reactions. Cramer and Bowman measured the rate constants for chain transfer (KCT) 
and homo-polymerisation (KH) respectively for a stoichiometric thiol-acrylate system and calculated 
the ratio (KH /KCT) to be 1.5 while for allyls the amount of homo-polymerisation was only a few 

























polymerisation is that carbon-carbon bonds are formed on the expense of thio-ether bonds. Thiol-
ene reactions ends by radical termination, which occur when two radicals of any origin recombines. 
 A general advantage of thiol-ene crosslinking methods is that many solvents can be 
used, also aqueous, and that no leaving groups are formed. A disadvantage is the large degree of 
side-reactions, which form non-degradable carbon-carbon bonds, and the need of a potentially toxic 
initiator. 
 
However, thiol-ene addition is a versatile method to form hydrogels and many different “thiol” and 
“ene” combinations are reported (Rydholm et al. 2007; Aimetti et al. 2009; Benton et al. 2009; Diaz 
et al. 2010; Lundberg et al. 2010). The use of those systems for drug delivery purposes is described 
later. 
 
1.1.1.2.3   Conjugate Addition 
A gelling method, which does not rely on radical chemistry, is the conjugate addition reaction (in 
some texts referred to as “Michael-type addition”). In this reaction, an α,β-unsaturated carbonyl 
reacts with a nucleophile (Scheme 2). The conjugating feature of the double bond, making the 
terminal carbon electrophilic and liable for a nucleophilic attack, renders this reaction possible. The 
selectivity of the nucleophile to react via conjugation, instead of an attack of the carbonyl carbon, 






Scheme 2: General conjugate addition mechanism where an α,β-unsaturated carbonyl reacts 
with a nucleophile. Red colour indicates the formed bond. 
 
From here on only conjugate addition of acrylates (R’ and R’’ = H) and thiols (RSH) will be considered. 
Acrylates are the least sterically hindered species among all α,β-unsaturated carbonyls, a feature 
which makes them easily accessible towards conjugate addition (McCarthy et al. 1994). Reactivity of 
thiols is determined by their individual pKa, which is a result of the surrounding structure. Adjacent 
electron withdrawing atoms or functional groups lowers the pKa, thereby making the proton easier 
to abstract and the thiol a better nucleophile, while an electron donating atmosphere has the 














the pKa it is crucial to control the pH of the reaction mixture during conjugate addition in order to 
control the reaction rate. 
Conjugate addition holds many potential advantages over other gel formation chemistries, such as 
photo-polymerisation and thiol-ene addition, as it can be performed without the addition of initiator 
or radiation and does not produce a leaving group. In addition, a solution of mixed pregel 
components spontaneously turns into a solid gel within minutes at physiological conditions (pH 7.4 
and 37° C). This feature has been used to design injectable hydrogels from PEG (Elbert et al. 2001) 
and PVA (Ossipov et al. 2008) to mention some synthetic hydrophilic polymers. 
 
The concept of using conjugate addition to form degradable hydrogels for drug delivery was 
essentially developed by Hubbell and co-workers during the last ten years (Elbert et al. 2001; Lutolf 
et al. 2001; Schoenmakers et al. 2004; Fittkau et al. 2005; Metters et al. 2005; van de Wetering et al. 
2005; Jo et al. 2009). Since then, others have adopted and developed the methodology to obtain 
properties desired for their applications. 
 
In this thesis conjugate addition was primarily used to form hydrogels from mono-functional or 
dendritic PEG based compounds bearing 4 or 8 acrylate groups crosslinked by 2- or 4-armed PEG 
thiols. In cases where the pregel compounds were not water soluble the related thiol-ene addition 
was employed instead. 
 
1.1.2   Crosslink Density and Swelling 
Following the gelling phase of a hydrogel, the gel is normally immersed in an aqueous phase, for in 
vitro or in vivo studies, where absorption of water swells the gel. The degree of swelling depends on 
factors such as molecular weight of the building blocks, concentration of building blocks during 
gelling and the number of crosslinking sites (DuBose et al. 2005; van de Wetering et al. 2005). Those 
parameters influence the level of crosslink density, which is a measure of the amount of 
covalent/ionic bridges between gel building blocks formed during gelling. Both the average molecular 
mass between crosslinks (Mc; g/mol) and the average mesh size (; Å) are used to represent crosslink 
density and these are calculated from experimental data (Andreopoulos et al. 1998). 
The mesh size represents the average distance between two crosslinks, in Ångström, 
and a short distance between crosslinks is equivalent to a high crosslink density. A normalised mesh 
size (Swollen/ Gelled) larger than 1 indicates that the mesh size for a swollen gel has increased 














initial increase in mesh size is a result of swelling where polymers in the gel network are stretched. 
Any further increase, however, indicates a lowered crosslink density resulting from bond breaking. 
Flory and Rehner developed the first equation to predict swelling of hydrogels (Flory et al. 1943). The 
equation is based on an entropy concept were two opposing forces either favours or disfavours 
swelling. 
The driving force for swelling is the entropy increase when water diffuses into the 
polymer network. This thermodynamic mixing of polymer and water is described by the Flory-
Huggins interaction parameter (Horta et al. 2005). The interaction parameter is an individual 
constant for each polymer-solvent system and indicates to which extent the polymer chains are 
hydrated (Horta et al. 2005). A gel made of hydrophobic polymers have a non-favoured interaction 
with water and does not swell much while gels made from hydrophilic polymers absorb large 
amounts of water and consequently swells to a great extent. A typical hydrogel swells until it 
contains up to 90-99% water by mass. 
The opposing force, which discourage further swelling, is a pure consequence from the 
swelling itself, since swelling brings tension into the gel network by stretching it and hence, lowers 
the entropy. Rubber-elasticity theories are used to describe this term in the equation. Swelling 
continues until equilibrium is reached, that is when the driving force of mixing polymer and water 
equals the contracting force of the elastic polymer network (Richter et al. 2008). 
Since the crosslink density is very important for the gel characteristics (DuBose et al. 
2005), the equation is rather rearranged to instead calculate crosslink density from experimental 
swelling data. 
A disadvantage of the Flory-Rehner theory is that crosslinks are assumed to form in 
the absence of solvent. However, the original equation has since been developed to account for the 
presence of water during gelling (Peppas et al. 2006), different degrees of swelling, both ideal and 
non-ideal hydrogel network formation (Metters et al. 2005) and for ionic gels (Sen et al. 2000). 
 Importantly, these calculated numbers only gives an average of the cavity size within 
the gel but not the range; and there is a range of mesh sizes since drugs larger than the calculated 
network dimensions still find paths through the gel and diffuses through it. 
 
1.1.3   Degradation 
Depending on the structural feature of the gel building blocks the resulting crosslinks may be non-
degradable or degradable. One method to obtain non-degradable gels is conjugate addition of vinyl 
















































Scheme 3: Formation of a hydrolytically stable crosslink by conjugate addition. 
 
Our group applied such hydrogel in a rat infarction model in order to improve pathological 
remodelling in the early healing phase (Dobner et al. 2009). The applied non-degradable gel acts as a 
mechanical support and resulted in initial benefits by increasing the wall thickness and reducing the 
wall dilatation, but there was also a substantial inflammatory response to the material. 
For many in vivo applications, however, it is desired to remove the applied hydrogel by 
degradation of the gel network into its respective water soluble building blocks. The advantage of 
using degradable hydrogels is a lowered exposure to the gel and its potential risk to cause an 
inflammatory response. Degradation can be achieved by proper design of either the polymer 
backbone or the crosslinks between individual polymers. Since swelling results in an increased 
surface area of the polymer network exposed to water the introduction of hydrolytically labile bonds 
increases the degradation rate of the network. Such degradation can be designed to occur over days 
to months, depending on desired application. 
 
1.1.3.1   Hydrolytic Degradation 
The hydrogel crosslinks used for the work in this thesis were formed by connecting the gel building 
blocks via ester bonds, consequently the gels were degraded by ester hydrolysis (Scheme 4). Esters 
however, are relatively stable at near-neutral pH (Zacchigna et al. 2008), but can be weakened. For 
example, introduction of an adjacent thio-ether moiety decreases the ester stability and increases its 
degradation rate (Hiemstra et al. 2007; Rydholm et al. 2007). The electron withdrawing effect of the 
thio-ether is used to explain the weakening effect of thio-ethers on esters (Schoenmakers et al. 2004; 






















The weakening effect is even greater if there are more electron withdrawing groups in the structure 
beyond the thio-ether (Jo et al. 2009). In addition to crosslink stability, the gel degradation rate is 
also related to crosslink density, where a higher density results in a slower degradation (DuBose et al. 
2005). 
 Previously (chapter 1.1.1.2.2), during the introduction of free radical polymerisation as 
a crosslinking method, the formation of carbon-carbon bonds was mentioned as a disadvantage. 
Scheme 5 shows the resulting bonds when acrylate-containing compounds are crosslinked via photo-
polymerisation, thiol-ene addition and conjugate addition, respectively. The ester crosslinks 
produced by photo-polymerisation are not weakened by an adjacent electron-withdrawing group 











Scheme 5: Three alternative routes to form ester containing gel crosslinks, red bonds are 
formed during crosslinking. 
 
Thiol-ene addition on the other hand introduces a thio-ether moiety, in this case at a distance of two 
carbons from the ester, which significantly increases the degradation rate of formed gels. However, 
the thiol-ene reaction of acrylates and thiols has a rather high degree of homo-polymerisation, which 
forms the more stable ester crosslinks (Scheme 5, middle right reaction product). The presence of 
those stable ester crosslinks makes the gel less degradable. Conjugate addition of acrylates and thiols 
(Scheme 5, lower reaction) on the other hand, results specifically in thio-ether weakened ester 
crosslinks and hydrogels formed by this method degrades readily. 
 
In case of gels formed by thiol-ene or conjugate addition the degradability originates from 
hydrolysable crosslinks. Alternative routes for the introduction of degradability include the design of 
the crosslinker itself, which may consist of hydrolytically degradable polyesters or enzyme sensitive 











































1.2   Approaches towards Controlled Drug Delivery 
Introduction of drugs into the blood circulation can take place in multiple ways, either directly via 
intravenous injection or secondary via transdermal, suppository, intramuscular or oral routes from 
where the drug is absorbed into the circulation. One of many challenges of drug delivery is to control 
the drug concentration in the blood, since a too low concentration is inactive while a too high 
concentration is toxic. Therefore much effort has been dedicated to master the kinetics of drug 
release where a constant dosing over time is the goal. 
 When a drug enters the circulation it has the potential to come in contact with every 
single cell accessible to the blood system. Consequently, a large number of healthy cells in different 
organs are exposed to unnecessary treatment. This is a major cause for unwanted side effects of 
drugs. As an alternative, if the drug was delivered locally to the very spot in need of treatment, many 
side effects could be avoided. A highly potential delivery concept meeting the demands of both 
controlled and local release is drug delivery through hydrogels.  
In such in vivo applications of hydrogels, the void of pathogens is of greatest 
importance. Depending on the hydrogel system, different sterilisation techniques are applicable. For 
UV cured implantable gels, UV sterilisation of the formed gel is suitable (Guvendiren et al. 2010), 
while for injectable gels it is possible to filter sterilise the gel precursor solutions prior mixing and 
injection (Bahney et al. 2011). 
 
The following text describes the main hydrogel based drug delivery systems. 
 
1.2.1   Encapsulation 
The simplest concept for drug delivery through hydrogels is the encapsulation method where the 
drug is embedded, or trapped, within a hydrogel. There are numerous methods of drug 
encapsulation of which the most common will be described here. In general, a homogeneous 
distribution of drug molecules throughout the gel network is achieved upon crosslinking a solution of 
pregel polymers in which the drug is also dissolved (Peppas et al. 2006). The drug molecules are then 
captured within the cavities of the gel during its formation. In contrast to these matrix systems there 
are reservoir systems where the drug is stored in the interior of the gel surrounded by a second gel 
barrier. 
 Drug delivery using micro- or nano-particles combine the attractive features of both 
systems. The gel feature contributes with a high water content (biocompatibility) and flexibility while 
the particle feature adds availability and the possibility to control the drug release rate by choosing 














ways, such as self-assembly of chitosan-PEG copolymers into micelle structures, precipitation of 
chitosan into nanoparticles or emulsion polymerisation methods to mention some. The delivered 
drug is either trapped in a reservoir system, homogeneously dispersed throughout the matrix or 
attached to the particle matrix (Hamidi et al. 2008). 
 Stimuli-responsive gels are characterised by their ability to react on changes in their 
physical environment, where the most studied systems respond to changes in pH (Sen et al. 2000) or 
temperature (Martellini et al. 1999). Other systems may respond to light, electric or ionic potentials 
or magnetic fields (Ahn et al. 2008). Some stimuli-responsive systems can be applied in-situ via 
injection, followed by gelling (He et al. 2008). Responsive behaviour could be designed for both 
chemical and physical gels, by the composition of the polymer backbone or the presence of pendant 
charged groups that bring the responsiveness. Gels made of poly(acrylic acid) are pH sensitive since a 
rise in pH deprotonates the acidic groups after which water diffuses into the gel to hydrate the 
charged groups and the gel starts to swell (Richter et al. 2008). For poly(acrylamide) a pH decrease 
protonates the amides, resulting in water covering the charged anions and the gel starting to swell 
(Richter et al. 2008). Poly(N-isopropylacrylamide) is the most commonly used polymer for thermo-
sensitive gels and when the temperature rise above a critical level for such gels, the polymer 
backbone loses its bound water, which forces the hydrophobic polymers together to minimise the 
unfavourable polymer-water contact area upon the gel network deswells (Lin et al. 2006). There are 
also systems where swelling is trigged by an increase in temperature (Ganji et al. 2009). 
 Encapsulated drug molecules in those stimuli-responsive gels are released upon 
swelling since the growing network allows the drug to diffuse out of the gel. The swelling behaviour 
of those systems is reversible. Therefore, if the external stimulus ends the gel shrinks and the drug 
release diminish (He et al. 2008). 
 
1.2.2   Covalent Incorporation 
The drug delivery described hitherto constitutes systems where the drug is stored or dispersed 
within the gel by different methods and the release is controlled by designing the physical 
parameters of the gel, such as crosslink density, degree of swelling and degradation rate. 
An alternative approach to controlled drug release is to covalently attach the drug to 
the hydrogel via a linker, thus, drug release is dependent on the breaking of a covalent bond. One of 
the main goals with drug release research is to deliver drugs into a biological system, hence when 
designing the in vivo breaking of such linker there is only a narrow range of chemistry available. The 
main approaches for releasing covalently bound drugs in vivo are hydrolysis, enzymatic digestion and 
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1.2.2.1   Hydrolytically Labile Linkers 
By connecting already existing functional groups on the drug, such as hydroxyl, carbonyl, amine or 
imine groups, with certain linkers release by hydrolysis is obtained, which can be tailored to occur at 
either acidic or physiological pH (West et al. 2005). Drug-gel linkers containing the acyl hydrazone 
moiety are acid-labile and used when drug delivery is directed to inflamed tissues, which are 
associated with acidic conditions (Farr et al. 1985), or other sites with lowered pH. Ulbricht et al. 
PEGylated the anticancer agent doxorubicin (Dox) via an acid labile acyl hydrazone containing linker 







Scheme 6: Acid catalysed hydrolysis of an acyl hydrazone drug-PEG linker, which recreates 
the original Dox structure. 
 
If instead the drug is attached via an ester, or ester in the vicinity of charged groups, the release can 
be tuned to occur at different rates at a physiological pH. In the work by Jo et al. release of covalently 
bound bovine serum albumin from a PEG hydrogel was obtained by hydrolysing the ester containing 
linker at a physiological pH (Jo et al. 2009). The release rate was furthered tailored by incorporating 
charged amino acids in line with the ester group. 
 
1.2.2.2   Enzymatically Labile Linkers 
Hydrogels in medical devices, such as dressings for improved wound healing, are specifically applied 
to the desired target, therefore the presence of certain cell types, such as epidermal, endothelial or 
inflammatory cells, is predictable (Singer et al. 1999). These cells secret enzymes, such as matrix 
metalloproteases (MMPs) and plasmin, which cleave specific peptide sequences within the 
surrounding fibrin network to provide passage for the migrating cells. By designing the drug-gel linker 
to contain particular peptide sequences corresponding to the substrate of these enzymes drug 
release mediated by enzymatic activity is obtained (Gombotz et al. 1995; Zisch et al. 2003; Benton et 
al. 2009). 
 Cell-demanded release of vascular endothelial growth factor (VEGF) was obtained by 
Zisch et al. by covalently attaching the factor via a MMP degradable linker (Zisch et al. 2003). In a 














endothelial cells increased in a dose-dependent manner upon plasmin mediated VEGF release from 
fibrin matrices with different VEGF loads (Ehrbar et al. 2005). 
 
1.2.2.3   Redox Labile Linkers 
The difference in redox environment between the inside and outside of a cell is used to design redox-
sensitive disulphide linkers. These are ideally stable in extra-cellular environments, but reduced as a 
result of cellular uptake resulting in intracellular drug release. The main agent considered for in vivo 
reduction of disulphides is the tripeptide glutathione, which is the most abundant thiol compound in 
the cytoplasm where the concentration is ~1-10 mM, compared to extracellular levels, ~2 µM (Hong 
et al. 2006). Importantly, the glutathione levels in some cancer tissues are significantly increased 
compared to healthy tissue (Yeh et al. 2006). Consequently, drug release depending on disulphide 
reduction can be used for targeted drug release. 
 In an in vitro study by Navath et al. glutathione mediated release of a model drug 
resulted in a 70% intracellular release of the drug load, while no release was detected extracellularly, 
from highly loaded (16 or 18 per carrier) dendritic drug conjugates (Navath et al. 2008). 
 Alternatively, the thiol containing model compound can be bound to a gold particle by 
self-assembly and exchanged by glutathione in vivo (Hong et al. 2006). 
 
1.3   Drug Release 
1.3.1   Mechanisms and Kinetics 
The elution of encapsulated or covalently attached drug may be controlled by different mechanisms 
and released with different kinetics, thus giving rise to different elution profiles. 
 
The most commonly considered mechanisms for drug release are swelling, degradation, diffusion or 
the breaking of a covalent bond. To significantly ascribe experimentally obtained release data to any 
of these mechanisms mathematical models are used. To mathematically describe an elution process 
there are multiple parameters to consider, such as the change of matrix dimensions by diffusion of 
water into the gel matrix and its degradation and concentration dependant diffusion of the drug out 
of the gel (Siepmann et al. 2000). Each model makes certain assumptions and is therefore only 
suitable for systems that fit those criteria. 
 A commonly used model to describe diffusion controlled elution is the Higuchi 
equation, but is only valid for non-swelling and non-degrading thin films and is therefore not 














 However, there are models that do consider swelling and degradation as a release 
mechanism, such as the Hixson-Crowell and Korsmeyer-Peppas equations (Shoaib et al. 2006). If 
experimentally obtained release data fits to the latter equation it may also be possible to distinguish 
whether the drug elution is primary controlled by the diffusion or swelling mechanisms or a 
combination thereof (Siepmann et al. 2001). 
 
However, these equations were developed to describe the elution of entrapped drugs. The release of 
covalently incorporated drugs is generally determined by the degradation rate of the covalent linker. 
Most of these links are designed to degrade by hydrolysis and gives rise to unique zero order elution 
profiles, unattainable by diffusion controlled release mechanisms (Siepmann et al. 2001; DuBose et 
al. 2005; Lin et al. 2006). To distinguish between burst, first order or zero order release kinetics 
obtained release data is compared to representative equations. A significant curve fitting to those 
equations indicates whether the release rate is dependent (first order) or independent (zero order) 
on the drug concentration (Shoaib et al. 2006). 
 
1.3.2   Controlled by Diffusion, Swelling or Degradation 
Drug release from a hydrogel scaffold is controlled by a number of factors, such as the drug 
incorporation method, the drug diffusion coefficient and the gel architecture. No matter which 
method or what type of gel is used the drug must travel out of the gel boundaries by diffusion to 
accomplish any effect on the surroundings, unless release is controlled by surface degradation of the 
gel. This logic explains why the diffusion-controlled mechanism is the most applicable mechanism to 
describe drug release from hydrogels. Smart designs and methodologies thus aim to control diffusion 
barriers in order to render the drug delivery sustained over a longer time period than a purely 
diffusion-controlled system provides (Peppas et al. 2006). There are two main hydrogel types where 



































Figure 5: Diffusion controlled drug delivery from reservoir and matrix systems, t = time. 
 
In the reservoir model a second hydrogel covers the drug-containing core as an effective diffusion 
barrier. In matrix systems the drug is homogeneously dispersed throughout the gel. In matrix 
systems affinity gels are smart expansions where the drug interacts with the gel network either 
through columbic or polar affinity, which lower the apparent diffusion coefficient and slows the drug 
elution. 
 To add complexity the gels made of hydrophilic polymers start to swell at t >0. For gels 
with high crosslink density the drug diffusion through the gel may be restricted making the drug 
release limited to the rate of swelling (Figure 6). Many stimuli-responsive gels belong to this category 
(He et al. 2008). The distinction between diffusion and swelling controlled drug delivery can be made 
using the Deborah number (De = λ/t) where the time scale of swelling, represented by the polymer 
relaxation time (λ), is compared to the time scale of diffusion (t). For a system controlled by swelling 
(De >1) the swelling is slow (big λ) and restricts the drug diffusion. For diffusion controlled systems 
the relation is the opposite (De <1), the diffusion is slow (large t) and limits the rate of drug elution 
(Lin et al. 2006). By varying the molecular weight (2-10 kDa) of 8-armed PEG acrylates van de 
Wetering et al. could control the gel swelling and regulate the release of a model compound from a 
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Figure 6: Swelling controlled drug delivery from a matrix system, t = time. 
 
For degradable hydrogels, the degradation rate of the gel network effects the drug release and is in 
some cases the rate-limiting factor (Figure 7). Degradation occurs when labile bonds within the gel 
network are cleaved, either by hydrolysis or enzymatic activity. There are two modes of hydrogel 
degradation, surface erosion and bulk degradation. Surface erosion would occur in a hydrophobic gel 
where surrounding water degrades the gel surface, but this is a rather theoretical situation since 
hydrogels contain huge amounts of water per definition. Instead surface erosion takes place in a 
hydrogel crosslinked by peptide sequences or enzyme degradable polymers when the enzyme 
activity is faster than the transport of enzymes into the gel interior. Most degradable hydrogel 
systems, though, can be ascribed to bulk degradation, where the degradation is equally likely to 
occur throughout the entire gel. A general example of bulk degradation is for a hydrogel where either 
the monomer building blocks are hydrolytically labile or the non-degradable monomers are 
crosslinked by a degradable crosslinker, or a combination of both. Hydrogel degradation facilitates 






Figure 7: Degradation controlled drug delivery from a matrix system, t =time. 
 
The reservoir and matrix hydrogel systems mentioned above may release the drug with an initial 
rapid burst followed by a prolonged release phase controlled by diffusion, swelling or degradation. 
Such burst may be decreased by increasing crosslink density or coating the drug containing gel with 


















































to fully describe the phenomenon many possible causes have been identified including material/drug 
interactions, fabrication conditions and sample geometry (Huang et al. 2001). 
 
1.3.3   Controlled by Hydrolysis 
 The complexity, and also the controllability of the drug eluting system, is taken to the next level by 
incorporating the drug covalently into the gel structure. Copolymerisation of drug and gel monomers 
incorporate the drug into the gel backbone, alternatively and more commonly used is the method to 
covalently attach the drug pendant from the polymer backbone. The character of the drug-polymer 
link determines whether the link degrades under acidic, alkaline or other conditions. Hydrazone 
bonds are acid-labile and drugs conjugated via these links are released in acid environment, such as 
certain inflammatory sites (Liu et al. 2010). Esters on the other hand degrade under slightly alkaline 
healthy in vivo-conditions (DuBose et al. 2005).  
 
The drug release described in this thesis is controlled by ester hydrolysis, probably in combination 
with diffusion, swelling and gel degradation. The drugs used (described later) were incorporated into 
the pre-gel polymers by conjugate addition, nucleophilic substitution or the 1,3-dipolar cycloaddition 
(HDC) of azides and terminal acetylenes (Act), also known s one Huisgen of the click reactions. In all 








Scheme 7: Conjugate addition, nucleophilic substitution and cycloaddition were used for 
drug incorporation in this thesis. Red bonds are formed during drug incorporation. 
 
As already stated in the case of gel degradability, esters in the vicinity of electron withdrawing groups 
are readily hydrolysed at a physiological pH. This is also the case for the drug-gel conjugates formed 
by conjugate addition and nucleophilic substitution depicted above. Schoenmakers et al. synthesised 
the drug-PEG conjugates shown in Scheme 8 which differ in the number of methylene groups spacing 
the carbonyl and the thio-ether moieties. The measured hydrolysis rate of the two conjugates turned 



































































Scheme 8: Two drug-PEG conjugates with different release rates. 
 
To explain this feature molecular modelling experiments were conducted in order to calculate the 
atomic charge on the carbon of the carbonyl group. Calculations were performed for the above 
structures (Scheme 8) and also for the case where only one methylene group separates the ester and 
the thio-ether. The results revealed that the positive charge of this carbon decreases with an 
increased number of methylene spacers (Schoenmakers et al. 2004), which is a clear indication why 
the hydrolysis rate is also decreased. Later research has shown that even the structure beyond the 
thio-ether moiety affects the ester degradation rate. In experiments where different amino acids 
were incorporated in line with the thio-ether it was obvious that the presence of electron 
withdrawing groups act to decrease the ester stability in the same fashion as the thio-ether itself (Jo 
et al. 2009). 
 
Using the HDC reaction instead results in a triazole moiety connecting the drug and the polymer 
network (Scheme 7, lower reaction). The ester closest to the drug is formed in a separate reaction 
prior to incorporation and is not weakened by electron withdrawing species. 
 Normally cycloadditions proceed through a concerted mechanism. However, 
molecular modelling and experimental data favours a stepwise catalytic cycle for the HDC reaction. 
Roughly, the cycle can be described by four major steps (Scheme 9); an initial formation of a π-
complex between the alkyne and the Cu(I) catalyst dimer whereupon the alkyne is deprotonated, the 
introduction of the azide into the complex followed by intra-complex rearrangements to form the 























The HDC reaction is unusually robust as it tolerates a wide range of pH values (5-12), can be 
performed over a wide range of temperatures (0-160° C) and tolerates the presence of water and 
oxygen. In addition the HDC always give 1,4-substituted products and proceeds approximately 107 
times faster than the uncatalysed counterpart (Hein et al. 2008). 
 A disadvantage with this particular click reaction is the requirement of a copper 
catalyst. Although copper is an essential element to maintain normal body functions and has also 
been used with success to treat tumours, excessive amounts lead to the development neurological 
disorders such as Parkinson’s disease and Alzheimer’s disease (Wang, T. et al. 2006). However, the 
copper catalyst can be reduced to undetectable levels from click formed hydrogels by washing with 
ethylenediaminetetraacetic acid (EDTA) solution (Malkoch et al. 2006). 
 
Two alternative mechanisms for release of tethered drugs by hydrolysis are proposed by Dubose et 
al. The dominant mechanism is primary release where the ester connecting gel and drug is 
hydrolysed and the drug released in its unmodified form. Alternatively, by cleaving esters further 
away along the PEG chain, or a combination of esters within the gel network, a drug-PEG conjugate is 
released, making it secondary or higher order release (DuBose et al. 2005). For the PEG gels studied 
by DuBose et al. (PEG-acrylate crosslinked by dithiothreitol with simultaneous incorporation of a 
thiolated dye) the amount of primary release was higher than 90%. 
 
1.4   Cardiovascular Diseases 
The specific interest of our research group (Cardiovascular Research Unit) concerns the treatment of 
cardiovascular diseases (CVDs). Therefore drugs with potential to ameliorate the healing of different 
aspects of CVDs were chosen to benchmark the hydrogel concepts developed in this work. 
Additionally, the use of drugs with combined anti-inflammatory and cardioprotective properties is 
beneficial in case the implanted gels would produce an inflammatory response. 
 
CVDs is a collection term for a number of pathologies concerning the heart and the arteries supplying 
it with oxygen rich blood, but in a wider interpretation CVDs also include the general vascular system 
throughout the body. Statistics for the United Kingdom (Stojkovic et al.) revealed that 0.2% of the 
population suffered from a heart attack in 2010 and one third of all deaths in the UK was a result of 
CVDs (Scarborough et al. 2010). In fact, CVDs are the major cause of death worldwide accounting for 
29% of all deaths (Mathers et al. 2004). 
 Several risk factors for developing CVDs have been identified giving a sad picture of 














physical activity, high blood pressure, dyslipidaemia, diabetes and genetic factors (Blom et al. 2005; 
Brunzell et al. 2008). The positive aspect would be that irrespective of which high risk group an 
individual belongs to, going from a low to a moderate fitness level would approximately half the 
relative risks for CVDs (Blair et al. 1989). 
 The extreme of CVDs is when a blood vessel gets blocked as a consequence of the 
eruption of atheroma, resulting in an ischemic region with reduced access to oxygen. If such an event 
occurs in the coronary arteries, supplying the heart muscle with oxygen, it is called a myocardial 
infarct (McMurray et al.), generally known as a heart attack. The heart muscle cells lacking oxygen 
will not survive this state, causing a reduced access of pumping force for the heart. If adequate help 
is available the affected area of the heart can be minimised. But the time window for such rescue of 
viable myocardium is narrow, only a few hours (Ertl et al. 2005). 
A heart attack initiates an intensive activity in the infarcted region in order to heal and 
minimise the damage. The mechanical response to an infarct may involve hypertrophy which is an 
attempt to compensate for lost heart muscle tissue but at the end may result in heart failure (Katz 
2002). The biological wound healing has three major but overlapping phases, an initial inflammation 
which starts within hours, followed by tissue formation and tissue remodelling starting after days and 
weeks respectively (Singer et al. 1999; Ertl et al. 2005). The wound healing phases all have in 
common the migration of cells that produce growth factors to coordinate the healing procedure 
(Singer et al. 1999; Vanhoutte et al. 2006). However, for wound healing in the heart post MI, the lack 
of blood supply aggravates the situation since cells cannot migrate in an ischemic region. At the end, 
the inherent wound healing mechanism has repaired the wound but not regenerated its original 
functions. It is at this stage cardiovascular researches want to change the natural proceedings of the 
biological wound healing routs by gentle manipulation with drugs and controlled delivery methods 
(Andreadis et al. 2006; Gurtner et al. 2008). As an alternative to drug treatments, the use of stem-
cells for cardiac recovery is currently under investigation (Segers et al. 2008). 
 
At present, the clinical treatments to prevent further CVD related complications are of surgical or 
medical character, or a combination thereof, depending on the nature of the MI. The surgical 
interventions consist of percutaneous angioplasty, with or without the placement of a stent. If 
several of the coronary arteries, supplying the heart muscle with oxygen rich blood, are narrowed, 
there may instead be the need of an open chest by-pass operation for one or more of the blocked 
arteries. 
The three main drug classes for medical treatment of post MI patients are angiotensin-














angiotensin receptor blockers (Cohn et al. 2001) and -blockers (Freemantle et al. 1999; Cruickshank 
2010). These drugs are particularly used for the management of cardiac arrhythmias, 
cardioprotection post MI in order to prevent congestive heart failure and to prevent stroke for 
patients with hypertension. 
 
1.4.1   Rapamycin 
Rapamycin is a naturally occurring macroloid drug with a broad range of anti-inflammatory and 
immunosuppressant action. All documented effects of Ra action origins from its inhibition of the 
mammalian target of Ra (mTOR). By doing so a wide range of therapeutic effects is set off. A visual 
effect is the striking similarity between rapamycin-treated and starved cells, which is due to the 
mTOR signalling pathway being responsible for cell growth in response to nutrients. The complex is 
responsible to keep a balance between protein synthesis and degradation such that the cell can 
rapidly adjust mass accumulation to a level appropriate to the nutrient supply (Schmelzle et al. 
2000). The mTOR also up-regulates the mammalian translational machinery upon elevated levels of 
amino acids and growth factors. 
 
1.4.1.1   The Effect of Rapamycin on Cardiovascular Diseases 
By inhibition of mTOR, the hub of the protein synthetic machinery, Ra exerts an avalanche of activity 
whereof many routes improve the detrimental effects of most stages of CVDs. 
 The starting point of many CVDs is vascular inflammation, which is reduced upon Ra 
treatment (Zhao et al. 2009). The mechanism of this involves inhibition of mTOR that regulates the 
response of major inflammatory cell types (Weichhart et al. 2008) and alters protein expression (Ma 
et al. 2007). 
 If vascular i flammation progress and the diseased vessels become occluded, grafting 
or by-pass surgery might be necessary. A common problem at the site of surgical injury and 
implanted stents is deposition of crosslinked fibrin, which may give rise to restenosis. Traditionally Ra 
is used to coat stents (Venkatraman et al. 2007), where the drug inhibits migration and proliferation 
of vascular smooth muscle cells (Sakakibara et al. 2005; Yallapu et al. 2008) -the main cause of 
restenosis. Formation of in-stent neointimal hyperplasia, the initial stage of restenosis, was 
eliminated in Ra treated stents (~2 mm2) compared to standard uncoated stents (~37 mm2) at six 
months (Morice et al. 2002). Rapamycin also improves long-term graft survival by lowering the 
immune response towards the graft. More specifically Ra influences the population of T-cells and 
Dendritic cells, which are the two main inflammatory cell lines when it comes to controlling 














activation. Dendritic cells produce interleukin-18 that is a pro-inflammatory cytokine closely 
connected with allograft rejection and vascular diseases. Rapamycin treatment inhibits the 
production of this inflammatory marker in vivo (Ko et al. 2008). 
 If grafting or by-pass surgery could not prevent a MI, there is still potential in Ra 
treatment, which has shown excellent ability to quench pathological coronary hypertrophy post MI 
(Shioi et al. 2003; McMullen et al. 2004; Shiojima et al. 2005), due to mTOR inhibition (Boluyt et al. 
2004; Proud 2004). Moreover, mTOR inhibition post MI also attenuates adverse left ventricular 
remodelling expressed as a significantly smaller infarct size (Buss et al. 2009). 
 The effects on post MI events of mTOR inhibition are truly powerful. Treatment 
initiated as late as 3 days post MI significantly attenuated myocardial remodelling and reduced 
hypertrophy. And after ending a one-month lasting treatment, there was still clear evidence of the 
improvements from mTOR inhibition after an additional two months (Buss et al. 2009). Finally, Ra 
treated mice increased their median and maximal lifespan by approximately 10% (Harrison et al. 
2009). 
 
No matter how potentially useful a drug is, the desired therapeutical effects will only be reached with 
the correct application of the drug. Prolonged systemic treatment with Ra resulted in side effects in 
as many as ~20% of the participating patients (Stojkovic et al. 2010). In contrast, when locally applied 
in a drug eluting stent application no adverse effects were attributable to the Ra coating of stents 
(Morice et al. 2002). These findings encourage the development of targeted drug delivery systems 
such as in situ forming hydrogels 
 
1.4.1.2   Controlled Release of Rapamycin 
The anti-inflammatory and immunosuppressant properties of Ra were investigated in numerous 
studies of stent coating (Venkatraman et al. 2007) and anti-rejection of transplanted organs 
(Gaumann et al. 2008). For improvement of implanted materials the standard approach is to blend 
Ra with a polymer carrier, prior to application to stents or other devices. Such approaches were 
developed by Wang et al. and Alexis et al. where Ra was homogeneously dispersed within a 
degradable PLGA matrix (Alexis et al. 2004; Wang, X. et al. 2006). The resulting elution profiles where 
biphasic for the two cases with an initial diffusion controlled release followed by a more rapid release 

























Figure 8: Rapamycin release from a PLGA coated stent. The graph is adapted from Alexis et 
al. (2004). 
 
To prolong the elution time of Ra Chen and co-workers trapped the drug in PEG containing triblock 
micelles, which were further embedded in a chitosan and PEG based hydrogel. Stents coated with 
this hydrogel maintained drug elution during a period of 190 days with a non-zero order profile (Chen 
et al. 2009). 
 
A range of both systemic and local delivery formulations of Ra, with potential to be used for anti-
rejection therapy, has been developed. These approaches include the entrapment of Ra in various 
micelles or nanoparticles. Micelles made from diblock PEG-PCL resulted in a 6 day release controlled 
by diffusion (Forrest et al. 2006). Figure 9 shows the elution profile from photo-polymerised poly(N-
isopropylacrylamide) hydrogel nanoparticles carrying entrapped Ra (Reddy et al. 2008). The profile is 
representative for many of the reported Ra delivery approaches in the literature (Forrest et al. 2006; 










Figure 9: Rapamycin release from poly(N-isopropylacrylamide) nanoparticles. The graph is 






















Apart from two commercially available synthetic derivatives of Ra, Everolimus and Temsirolimus, 
introduced between 2007 and 2011 for prevention of organ rejection and treatment of cancer 






Figure 10: Everolimus and Temsirolimus are Ra prodrugs substituted by the hydroxyl group 
at position 40. 
 
However, one patent reports on PEGylation of Ra (Lee et al. 1998), and the Ra-PEG derivative was 
further used for applications such as anti-tumour treatment in combination with PEGylated 17-
hydroxywortmannin (Yu et al. 2005). Other related patents describe the use of Ra trapped in sugar 
coatings (Nagi 1998) or in the hydrogel core of microcapsules (Sharp et al. 2012) for oral and topical 
administration, dissolved in aqueous N-N-dimethylacetamide for intravenous injection (Waranis et al. 
1996), or trapped in polymeric coatings to be used with implantable devices, such as stents (Castro et 
al. 2010; Hossainy et al. 2012), to mention some applications. 
 
As pointed out in the text above, a sustained Ra elution is obtainable by intelligent design of the drug 
entrapment, but the release is controlled by diffusion and/or degradation and the resulting elution 
profiles are not of zero order character. A zero order drug dosing elution profile is desired since the 
resulting drug concentration is more or less constant during the elution period, and the potentially 
toxic levels first order and burst release may result in are avoided. Thus, the apparent lack of 
controlled Ra release gives rise to a demand for devices showing both a sustained and zero order 
release. 
 
1.4.2   Dexamethasone 
Dexamethasone (Dex), a synthetic steroid hormone binding to the glucocorticoid receptor, acts 
through slow genomic (Cole 2006) or rapid non-genomic (Lowenberg et al. 2007) mechanisms to 
exert a wide range of activities in the human body. Due to its anti-inflammatory and 
immunosuppressant properties, Dex is regularly used for clinical treatment of anaphylactic shock and 
inflammatory diseases such as rheumatoid arthritis and asthma. However, prolonged systemic use of 
the drug has undesirable side effects such as obesity, diabetes, immune suppression and 














locally to reduce inflammation from implanted devices such as screw-in pacemaker leads and ocular 
inserts (Baeyens et al. 1998), to prevent restenosis in vascular stents (Koenig et al. 2009) and is also 
available in a variety of topical ointments/gels/solutions (McGuigan et al. 1986; Chandra et al. 2000). 
 
1.4.2.1   Controlled Release of Dexamethasone 
As Dex has been shown to be effective also in a variety of applications, it is not surprising that there 
is a growing body of literature describing its controlled release. Dex has been incorporated in and 
released from PLGA microspheres (Kim, D. H. et al. 2006; Zolnik et al. 2008), polypyrrole coatings 
(Wadhwa et al. 2006), PEG containing copolymers crosslinked by photo-polymerisation (Norton et al. 
2007), PLGA nanoparticles in PVA-gels (Cascone et al. 2002; Patil et al. 2007) and from degradable 
PLGA scaffolds made by gas-foaming/salt leaching (Yoon et al. 2003).  
On the patent side, Dex has been incorporated and released from; drug delivery 
reservoirs filled with hydrogels based on hyaluronic acid (Jolly et al. 2009), PVA-gels for 
administration via transdermal or transmucosal routes (Kuribayashi et al. 2006) or hydroxymethyl 
methacrylate-based gels in combination with a growth factor in order to improve wound healing 
(Schultz 2003), to mention some applications. 
 
In these and many other examples, Dex was incorporated by physical entrapment and was released 
by a diffusion/swelling mechanism and/or with degradation of the matrix. A representative elution 
profile for such release is shown in Figure 11 where Dex is released from a silicone polymer matrix, 



























In contrast, Zacchigna et al. studied the effect of covalent PEGylation of Dex by conjugating Dex-
succinate with mono-PEG-NH2, more than 65% of the drug was released by esterase action within 24 
hours (Zacchigna et al. 2008). To obtain long term sustained drug delivery Nuttelman et al. covalently 
coupled Dex to methacrylated PEG, via a linker containing 2, 4 or 6 degradable lactic acid units, which 
were formed to hydrogels by photo-polymerisation. By encapsulating human mesenchymal stem 
cells in the gels an induced osteogenesis was verified as Dex was hydrolytically released (Nuttelman 
et al. 2006). The hydrogels eluted less than 27% of the load in approximately 30 days. 
 Dex has also been conjugated with molecules for targeting specific tissues. Both Dex-
succinate-dextran and Dex-21-sulphate sodium are colon-specific pro-drugs, which release Dex in 
contact with colon or cecum specific enzymes (Pang et al. 2002; Kim, I. H. et al. 2006) 
 Controlled release by making use of local conditions in inflamed tissues was obtained 
by PEGylating Dex via an acyl hydrazone linker and forming micelles with a PEG containing block 
polymer (Howard et al. 2011). Alternatively, a Dex-acyl hydrazone-2N3 derivative was copolymerised 
by the HDC click reaction with a mixture of mono-PEG-Act and PEG-2Act to obtain an injectable 
conjugate which released Dex over approximately 17 days in an acidic environment mimicking 
rheumatoid arthritis (Liu et al. 2010). The obtained acid catalysed zero order release of Dex is shown 
in Figure 12. A significantly lower anti-inflammatory response was proved in a subcutaneous mouse 
model for implanted hyaluronic acid hydrogels covalently linked via a hydrazide moiety to Dex 










Figure 12: Hydrolytically released Dex from a PEG-Dex conjugate at different pH. The graph is 
adapted from Liu et al. (2010). 
 
These reports show the possibility to elute Dex over a prolonged period of time by encapsulating the 
drug, while site specific release of Dex, either by enzymatic activity or hydrolysis in an acidic 
environment is less sustained. Therefore, methods for a sustained and controlled release at 














1.5   Hypothesis and Aims 
As noticed by the reader, in these opening chapters, drug release from hydrogels is a complex 
subject and controlled zero order release is not often observed in the literature. 
 
To obtain such release, the author behind this thesis worked according to the following hypothesis; 
controlled, zero order release, of rapamycin, dexamethasone and atorvastatin from injectable and 
degradable hydrogels can be achieved by covalent attachment of the drugs to the hydrogel matrices 
via hydrolytically degradable bonds. 
 
The specific aims with the work in this thesis are; 
 
Regarding hydrogels: 
 To produce acrylated and thiolated PEG-based building blocks, which render injectable 
hydrogel formulations that solidifies spontaneously under biological conditions. 
 To obtain gels that degrade hydrolytically under biological conditions and that the 
degradability is tuneable by the crosslinking chemistry and by varying the number of 
crosslinking sites. 
 
Regarding drug elution: 
 To render the hydrophobic drugs Ra, Dex and atorvastatin water soluble by covalent 
conjugation with PEG, and that covalent incorporation into hydrogels and the subsequent 
hydrolytically controlled release of these drugs leads to a sustained elution. 
 To obtain drug release, which follows zero order kinetics and that the released drugs retain 
their biological activity. 
 To tune the rate of drug elution by the chemical environment next to the drug-gel linker.  
 To distinguish between zero and first order or burst release kinetics by using the zero order 





























1.6   Strategy 
To produce a biocompatible slow release drug delivery system there are many parameters to 
consider. The following text will take the reader through the strategic decisions made regarding the 
options of building blocks to drug eluting mechanisms, while briefly repeating the most important 
arguments on how to achieve the set out aims at each particular level (Figure 13, Level 1-6). 
 
Level 1 and 2: 
The polymers used to build a hydrogel scaffold could be of natural origin or synthetically produced, 
hydrophobic or hydrophilic to mention the fundamentals. The synthetic hydrophilic polymer PEG is a 
well-favoured material in pharmaceutical applications due to its inertness, non-toxicity and its 
elimination via both renal and hepatic pathways (Veronese et al. 2005) and was thus chosen. The 
strategy was to produce biocompatible hydrogel scaffolds, suitable for drug delivery, by co-gelling 
PEG based multi-arms and crosslinkers with PEGylated drugs. 
 
Level 3: 
The mode of gelling determines gel properties such as swelling degree, degradation rate and 
mechanical strength. The aim with this thesis was to produce a solid gel that keeps intact for a 
desired period of time, but eventually degrades and is cleared from the body. The strategy to obtain 
these properties was to gel the PEG building blocks by chemical gelling methods and the introduction 
of hydrolytically labile ester crosslinks rendered the gels degradable. 
 
Level 4: 
The choices of gel architecture (linear, star shaped, dendritic etc.) and assembling mode (matrix, 
reservoir, micro/nano-spheres, embedded spheres etc.) affect gel properties and drug elution 
kinetics. In order to obtain a range of drug eluting properties the strategy was to develop two 
different matrix approaches towards controlled drug delivery; one using either 2- or 4-armed mono-
functional PEGs where the drug is pending at the terminal of the polymer and the other approach 
using bi-functional 2- or 4-armed PEG-based dendritic structures of first or second generation. 
 
Level 5: 
To obtain formulations, which solidify spontaneously at biological conditions, and thus can be 
injected for in situ formation, the conjugate addition reaction was preferred for the gelling step. In 

































































Drugs delivered by hydrogels can be released by different mechanisms (diffusion, swelling, 
degradation, hydrolysis, enzymatic activity etc.) resulting in various elution profiles (burst, zero or 
first order etc.). The sustained and constant drug release described by zero order kinetics is desired 
in many applications. To obtain such release for the chosen drugs, Ra and Dex, the strategy was to 
covalently incorporate these drugs into the pregel polymers, via hydrolytically labile esters, by 
conjugate addition (Conj. Add.) or nucleophilic substitution (Nuc. Sub.) in the mono-functional 
approach and by click chemistry (Click) in the dendritic approach. 
 In addition, atorvastatin, an HMG-CoA reductase inhibitor, was initially investigated for 
the mono-functional approach (Appendix I), but was put on hold in favour of development of Ra and 
Dex delivery. 
 
Using biocompatible PEG building blocks gelled by conjugate addition opens up for the possibility to 
locally inject the pregel solution into the targeted tissue making these gels very useful in applications 
where localised anti-inflammatory action and/or immunosuppression is required, but especially 
where in situ gel formation is an additional requirement. By applying these gels in situ at the very site 
in need of stimulus, the drug elution is limited to the surrounding tissue, thus, avoiding systemic 
exposure, which is often associated with a range of unwanted side effects.  
Level 6 . . . . . . . . .
Level 1 . . . . . . . . .
Level 5 . . . . . . . . .
Level 3 . . . . . . . . .














 By creating such a hydrogel platform, the ground is laid for the further development of 
applications such as an injectable treatment for improvement of MI recovery and coatings for 






























2   MATERIALS and METHODS 
 
ll chemicals were obtained from commercial sources and of reagent grade or higher, except 
where otherwise stated. The two drugs and some of the polymers were obtained from 
particular sources and will therefore be specified. Dexamethasone was obtained from Pharmacia & 
Upjohn and the following chemicals were purchased: rapamycin (Zhou Fang Pharm Chemical, 
Shanghai, China), 10PEG-4OH (Shearwater Polymers, Huntsville, USA) 20PEG-8OH (Nektar 
Therapeutics, Huntsville, USA) and 10nPEG-4SH (Creative PEGworks, Winston Salem, USA). 
 
2.1   Nomenclature 
mPEG-nOH  n armed polyethylene glycol (PEG) with a molecular mass of m kilo 
  Dalton (kDa) 
msPEG-nX PEG conjugates with n arms and a molecular mass of m kDa where X is 
either acrylate (Ac), vinyl sulphone (VS) or thiol (SH) groups, s denotes 
whether the thiols are attached via an ester linkage (s= d for 
degradable) or not (s= n for non-degradable) 
Ra-nX  mono (n= 1) or di (n= 2) functionalised rapamycin (Ra) where X is either 
  acrylate (Ac) or iodoacetic ester (IAE) groups 
RaX-dPEG-2SH/3SH mono functionalised RaX conjugated with 2dPEG-2SH or 10dPEG-4SH, X 
is either acrylate (Ac) or iodoacetic ester (IAE) groups 
PEG-G-nX1-nX2 dendritic compounds of first (G= G1 or 4arm-G1) or second (G= G2) 
generation where n is the number of functional groups; X1= acetylene 
(Act) or Dex, X2= acetonide protection (Castro et al.), OH or Ac 
 
2.2   Syntheses of Gel Building Blocks 
2.2.1   Preparation of the Multi-arms 
The multi-acrylate and multi-vinyl sulphone were the bulk materials for Ra containing gels and their 
synthesis protocols were adapted from the literature (Elbert et al. 2001; Dobner et al. 2009). 
 
Synthesis of 20PEG-8Ac (1): Star shaped 20PEG-8OH (10 g, 4.0 mmol OH) was dissolved in toluene 
(500 ml) and dried by azeotropic distillation. The residue (~400 ml) was cooled on ice and diluted 
with DCM (200 ml). Freshly distilled triethylamine (TEA; 10 ml, 10 mmol, of a stock solution of 7 ml 
TEA in 50 ml dichloromethane; DCM) was added. Acryloyl chloride (AcCl; 10 ml of a stock solution of 















reaction was left with stirring overnight. The reaction mixture was filtered to remove insolubilities 
and the volume reduced (to ~60 ml) prior to precipitation in ice cold diethyl ether (600 ml). The 
precipitation was repeated twice from DCM (60 ml) into ice cold diethyl ether (600 ml). The product 
was further purified by dialysis (cut off value =1 kDa) and freeze dried to obtain a slightly off white 
powder (6.9 g, 68%, 94% purity by nuclear magnetic resonance; NMR). 
 
1H NMR (300 MHz, CDCl3): δ= 3.43-3.80 (m; PEG), 4.29 (t, J= 5.5 Hz, 16H; -PEGOCH2CH2Ac), 5.81 (dd, 
J= 10.4 and 1.3 Hz, 8H; AcCis), 6.13 (dd, J= 17.4 and 10.5 Hz, 8H; Ac) and 6.40 (dd, J= 17.4 and 1.2 Hz, 
8H; AcTrans) parts per million (ppm). 
 
Both the product purity and a high degree of substitution were verified by a gelling test where 1 (200 
mg/ml PBS-2) was mixed with a solution of 2dPEG-2SH (3) at a stoichiometric ratio and a final 
concentration of 14% (w/v PBS-2). A gel (50 µl) was formed from the pregel solution and incubated 
(37° C). The gelling was assessed at regular intervals and was considered to occur when the gel was 











Synthesis of 20PEG-8VS (2): Star shaped 20PEG-8OH (20 g, 8.0 mmol OH) was dissolved in DCM (200 
ml) and dried over molecular sieves (4 Ångström; Å) overnight. The molecular sieves were removed 
by filtration and NaH (65 % in oil; 1.5 g, 41 mmol) was added in portions followed by addition of DCM 
(300 ml). The solution was then purged with argon gas for five minutes by bubbling. Divinyl sulphone 
(40 ml, 398 mmol) was added in one portion, the solution was bubbled with argon (30 min) and left 
to react for two days in darkness. Addition of glacial acetic acid (2.5 ml, 44 mmol) quenched the 
remaining NaH and protonated the product. The volume was reduced (to ~100 ml) prior to 

































removed by vacuum. The precipitation was repeated twice to obtain a slightly off white powder (6.8 
g, 32%, ~100% purity by NMR). 
 
1H NMR (300 MHz, CDCl3): δ= 3.25 (t, J= 5.7 Hz, 16H; -PEGOCH2CH2VS), 3.58-3.72 (m; PEG), 3.89 (t, J= 
5.7 Hz, 16H; -PEGOCH2CH2VS), 6.07 (d, J= 9.9 Hz, 8H; VSCis), 6.38 (d, J= 16.7 Hz, 8H; VSTrans) and 6.80 











2.2.2   Preparation of the Thiol Crosslinkers 
PEG-2OH with various molecular masses (0.6, 0.9, 1.5 and 2 kDa) were conjugated with 3-
mercaptopropionic acid using the same method, as previously described (Nie et al. 2007). Details are 
given in the case of 2PEG-2OH. 
 
Synthesis of 2dPEG-2SH (3): Linear 2PEG-2OH (10.0 g, 10 mmol OH), 3-mercaptopropionic acid (4.3 
ml, 49 mmol) and para toluene sulphonic acid (pTSA; 95 mg, 0.50 mmol) were dissolved in toluene 
(150 ml). The reaction mixture was heated (140° C) and refluxed in a Dean-Stark apparatus set up 
overnight. The solution was cooled on ice and the volume reduced prior to precipitation in cold 
diethyl ether. The precipitation was repeated, this time from DCM (20 ml) into cold diethyl ether 
(200 ml) and the collected product was vacuum dried (9.9 g, 90%, 99% purity by NMR). 
 
1H NMR (300 MHz, CDCl3): δ= 1.62 (t, J= 8.1 Hz, 2H; -SH), 2.59-2.64 (m, 4H; -OCOCH2CH2SH), 2.67-
2.75 (m, 4H; -OCOCH2CH2SH), 3.32-3.82 (m; PEG) and 4.20 (t, J= 4.7 Hz, 4H; PEG-CH2CH2OCO-) ppm. 

















































Synthesis of 10dPEG-4SH (4): Star shaped 10PEG-4OH (9.5 g, 3.8 mmol OH), 3-mercaptopropionic 
acid (3.5 ml, 40 mmol) and pTSA (77 mg, 0.40 mmol) were dissolved in toluene (150 ml). The reaction 
mixture was heated (135° C) and refluxed in a Dean-Stark apparatus set up over the day. Toluene was 
removed by evaporation and the crude product was precipitated twice from DCM (20 ml) into cold 
diethyl ether (250 ml). The collected product was vacuum dried (8.7 g, 88%, 99% purity by NMR). 
 
1H NMR (300 MHz, CDCl3): δ= 1.64 (t, J= 8.4 Hz, 4H; -SH), 2.61-2.67 (m, 8H; -OCOCH2CH2SH), 2.69-















2.2.3   Mono-functional Approach 
2.2.3.1   Preparations of Rapamycin Derivatives 
The precipitation protocol of RaAc (Viswanath et al. 2008) and the synthesis and PEGylation 
protocols of RaIAE (Plattsburgh et al. 1998; Yu et al. 2005) were adapted from the literature.  
RaAc was synthesised several times using different amounts of AcCl. The 
methodologies were similar in all cases, but details are only given for the batch further used for the 
PEGylation and gel incorporation steps. 
 
Synthesis of RaAc (5): Rapamycin (Ra; 278 mg, 304 μmol) and TEA (85 μl, 610 μmol) were dissolved 
in DCM (20 ml). AcCl (49 μl, 606 μmol) was separately dissolved in DCM (10 ml) and slowly added to 
the reaction mixture from a dripping funnel resulting in the formation of hydrochloric gas. The two 
reaction solutions were always kept in an argon atmosphere. The reaction was followed by thin layer 
chromatography (TLC; 70% ethyl acetate in n-hexane) and if Ra (Rf≈ 0.3) was not consumed within 2 
hours of reaction, additional amounts of AcCl and TEA were added (total addition: 8 eq/Ra). The 































a chloroform mixture of the product and silica. The product/silica mixture was then loaded to a 
column packed with silica (30 g) in hexane which was washed with an increasing gradient of ethyl 
acetate (EtOAc) in n-hexane (Hex), the product eluted at 50%. All fractions containing the product (Rf 
≈0.7) were pooled and the solvents co-evaporated with chloroform. The product was further 
dissolved in tert-butyl methyl ether, filtered and precipitated in n-heptane (Hep) to yield a slightly 
off-white powder (102 mg, 35%, 100% purity by NMR). 
 
High pressure liquid chromatography (HPLC) retention times for the Ra reference: 37.64 min and for 
compound 5: 40.95 min. 
 
Electrospray ionisation mass spectrometry (ESI-MS) of Ra: found (assigned) m/z= 814.5 (Ra-frag1), 
832.6 (Ra-frag1 + H2O), 846.6 (Ra-frag2), 864.6 (Ra-frag2 + H2O), 882.6 (Ra-frag2 + 2H2O), 931.6 (Ra + 
H2O), 936.6 (Ra + Na
+), 952.6 (Ra + K+) and 994.6 (Ra-adduct). ESI-MS of compound 5: found 
(calculated, assigned): m/z= 886.6 (886.6, Ra-frag1-Ac + H2O), 900.6 (900.6, Ra-frag2-Ac), 918.6 
(918.6, Ra-frag2-Ac + H2O), 936.6 (936.6, Ra-frag2-Ac + 2H2O), 990.6 (990.6, Ra-Ac + Na
+) and 1006.6 










Synthesis of RaIAE (6a and 6b): Rapamycin (250 mg, 273 μmol), 4-dimethylaminopyridine (DMAP; 
2.0 mg, 16 μmol), iodoacetic acid (61 mg, 328 μmol) and N,N’-dicyclohexylcarbodiimide (DCC; 67.7 
mg, 328 μmol) were dissolved in DCM (15 ml), placed on ice and left with stirring overnight. The 
reaction was followed by TLC (70% EtOAc in Hex) and the incomplete consumption of Ra (Rf ≈0.3) led 
to the addition of more iodoacetic acid (0.2 eq/Ra) and DCC (0.2 eq/Ra). The solvent was evaporated 
and the crude product absorbed on silica (1 g) by evaporating a chloroform mixture of the product 
and silica. The product/silica mixture was then loaded to a column with silica (20 g) packed in Hex 
and washed with an increasing gradient of EtOAc, the products eluted at 40% with only a small 





























and the solvents co-evaporated with chloroform to yield an off-white powder (6a: 192 mg, 65%, 
100% purity by NMR; 6b: 142 mg, 100% purity by NMR). 
 
HPLC retention times for the Ra reference: 37.64 min, compound 6a: 41.07 min and compound 6b: 
42.63 min. 
 
ESI-MS of compound 6a: found (calculated, assigned): m/z= 1000.5 (1000.5, Ra-frag1-monoIAE + 
H2O), 1014.5 (1014.5, Ra-frag2-monoIAE), 1032.5 (1032.5, Ra-frag2-monoIAE + H2O), 1050.5 (1050.5, 
Ra-frag2-monoIAE + 2H2O), 1099.6 (1099.5, Ra-monoIAE + H2O), 1104.5 (1104.5, Ra-monoIAE + Na
+), 
1120.5 (1120.5, Ra-monoIAE + K+) and 1162.5 (1162.5, Ra-adduct-monoIAE). ESI-MS of compound 6b: 
found (calculated, assigned): m/z= 1014.5 (1014.5, Ra-frag2-monoIAE), 1182.4 (1182.4, Ra-frag2-
diIAE), 1200.4 (1200.4, Ra-frag2-diIAE + H2O), 1218.4 (1218.4, Ra-frag2-diIAE + 2H2O), 1267.5 (1267.4, 
Ra-diIAE + H2O), 1272.4 (1272.4, Ra-diIAE + Na











2.2.3.2   Preparations of Ra-PEG conjugates 
The RaAc and RaIAE derivatives were conjugated with 2nPEG-2SH, mercaptoethanol, 0.6dPEG-2SH, 
0.9dPEG-2SH, 1.5dPEG-2SH, 2dPEG-2SH or 10dPEG-4SH using similar methods. Details are given for 
conjugation with 2dPEG-2SH and 10dPEG-4SH. 
 
Synthesis of RaAc-dPEG-3SH (7): RaAc (5; 25.9 mg, 26.8 μmol) was dissolved in MeCN (1.5 ml) and a 
solution of 10dPEG-4SH (4; 750 μl of 288.6 mg in 793 μl of 0.1 M NaHCO3, 26.8 μmol) was added. The 
reaction mixture was incubated at 37° C for 1 hour prior to freeze drying. The crude reaction mixture 
was redissolved in DCM (2.2 ml) and precipitated in cold diethyl ether (25 ml) to yield the product 













































The amount of Ra per gram product was determined by dissolving compound 7 (11.9 mg) in 100 ml 
of a 1:1 mixture of phosphate buffered saline (PBS-1) and ethanol (EtOH), reading the absorbance on 
a spectrophotometer (λ =279 nm) and calculating the amount of Ra using a standard curve made 












Synthesis of RaIAE-dPEG-3SH (8): Compound 6a (31.9 mg, 29.5 μmol) was dissolved in MeCN (1.6 ml) 
and diluted with of a solution of 10dPEG-4SH (4; 800 μl of 302.9 mg in 806 μl of 0.1 M NaHCO3, 29.5 
μmol). The reaction mixture was incubated at 37° C for 1 hour prior to freeze drying. The crude 
reaction mixture was redissolved in DCM (3 ml), filtered through a cotton plug and precipitated in 
cold diethyl ether (25 ml) to yield the product (289 mg, 87%). 
 
The amount of Ra per gram mixture was determined by dissolving compound 8 (15.6 mg) in 50% PBS-
1 in EtOH (100 ml), reading the absorbance on a spectrophotometer (λ =279 nm) and calculating the 










































































Synthesis of RaAc-dPEG-SH (9): RaAc (5; 7.5 mg, 7.7 μmol) was dissolved in acetonitrile (MeCN; 200 
μl) and a solution of 2dPEG-2SH (3; 17.0 mg, 7.7 μmol, in 100 μl of 0.1 M NaHCO3) was added. The 
reaction mixture was incubated at 37° C for 1 hour prior to freeze drying. The crude reaction mixture 





Synthesis of RaIAE-dPEG-SH (10): A mixture of RaMonoIAE and RaDiIAE (6a and 6b; 9.9 mg, 8.5 
μmol) was dissolved in a mixture of MeCN (200 μl) and methanol (MeOH; 200 μl) and a solution of 
2dPEG-2SH (3; 18.5 mg, 8.4 μmol, in 200 μl of 0.1 M NaHCO3) was added. The reaction mixture was 
incubated at 37° C for 2 hours prior to freeze drying. The crude reaction mixture was used without 






2.2.4   Dendritic Approach 
2.2.4.1   Preparations of Acetylene monomer anhydride 
The acetylene monomer anhydride was the main building block for the dendritic structures and was 
synthesised similarly to existing methods (Antoni et al. 2009) as follows: 
 
Synthesis of acetonide protected trizma (11): The hydrochloride salt of 2-amino-2-hydroxymethyl-
propane-1,3-diol (Trizma; 100 g, 635 mmol), 2,2-dimethoxypropane (118 ml, 963 mmol) and pTSA 
(5.2 g, 27 mmol) were dissolved in dimethylformamide (DMF; 600 ml) and stirred overnight. The acid 
was neutralised by TEA (4 ml, 29 mmol) followed by rotary evaporation of 2,2-dimethoxypropane 
and DMF at 60° C. The crude reaction mixture was redissolved in DMF (50 ml) and then diluted with 
EtOAc (950 ml). The hydrochloride salt of the product was neutralised by adding TEA (100 ml, 717 
mmol) and the precipitate was removed by filtration. The volume was reduced (to ~150 ml) and the 
product was precipitated in cold diethyl ether (1.5 l, cooled with dry ice) from a dripping funnel. The 
precipitate was collected on a filter and dried over vacuum to yield the product (75 g, 73%, 96% 

































1H NMR (400 MHz, D2O): δ= 1.41 (s, 3H; -CH3), 1.43 (s, 3H; -CH3), 3.53 (s, 2H; -CH2OH), 3.62 (s, J= 12.1 
Hz, 2H; -OCH2-) and 3.86 (d, J= 12.1 Hz, 2H; -OCH2-) ppm. 
13C NMR (100.6 MHz, D2O): δ= 22.53 (-CH3), 





Synthesis of succinic propargyl ester (12): Propargyl alcohol (104 ml, 1.8 mol) and DMAP (43.6 g, 
0.36 mol) were dissolved in DCM (1 l) and placed on ice prior to portion wise addition of succinic 
anhydride (214 g, 2.14 mol) which dissolved upon stirring overnight. NMR confirmed the complete 
consumption of propargyl alcohol (CHCCH2OH, δ= 4.25 ppm) and the excess of succinic anhydride 
was quenched by addition of 200 ml distilled water. The crude reaction mixture was purified by 
extraction with weak acid (6X 200 ml 10% w/v NaHSO4) whereupon the organic phase was dried with 
MgSO4, filtered to remove the solids and evaporated to yield the product (227.4 g, 81%, 100% purity 
by NMR). 
 
1H NMR (400 MHz, CDCl3): δ= 2.47 (t, J= 2.3 Hz, 1H; Act), 2.61 (m, 4H; COOHCH2CH2-), 4.62 (d, J= 2.3 
Hz, 2H; -OCH2CCH) and 10.95 (s, 1H, -COOH) ppm. 
13C NMR (100.6 MHz, CDCl3): δ= 28.28, 28.47, 





Anhydride formation of succinic propargyl ester (13): Compound 12 (227.4 g, 1.46 mol), was 
dissolved in DCM (350 ml) and cooled on ice. DCC (150.3 g, 0.73 mol) was added in portions and the 
reaction was stirred overnight. The precipitated dicyclohexylurea was removed by filtration and the 
solvent was evaporated to yield the product (129.1 g, 60%, 100% purity by NMR). 
 
1H NMR (400 MHz, CDCl3): δ= 2.49 (t, J= 2.3 Hz, 1H; Act), 2.71 (t, J= 6.6 Hz, 2H; -CH2CH2-), 2.81 (t, J= 
6.6 Hz, 2H; -CH2CH2-) and 4.70 (d, J= 2.2 Hz, 2H; -OCH2CCH) ppm. 
13C NMR (100.6 MHz, CDCl3): δ= 
















































Acetylene addition to acetonide protected trizma (14): Acetonide protected trizma (11; 39.7 g, 246 
mmol), and TEA (51 ml, 368 mmol) were dissolved in DCM (1.8 l) and placed on ice. Compound 13 (58 
g, 197 mmol), was dissolved in DCM (400 ml) and added to the reaction solution via a dripping funnel 
over 1h. After an additional hour 13C NMR revealed the consumption of the anhydride and the 
volume was reduced (to ~1 l). The solution was extracted with weak acid (5X 400 ml, 10% w/v 
NaHSO4) and mild base (5X 400 ml, 10% w/v Na2CO3) and stirred with MgSO4 overnight. The solids 
were removed by filtration, the solvent was evaporated and the remaining product was dried over 
vacuum (48.7 g, 83%, 98% purity by NMR). 
 
1H NMR (400 MHz, CDCl3): δ= 1.40 (s, 3H; -CH3), 1.41 (s, 3H; -CH3), 2.13 (s, 1H; -OH), 2.47 (t, J= 2.4 Hz, 
1H; Act), 2.55 (t, J= 6.8 Hz, 2H; -CH2CH2CONH-), 2.68 (t, J= 6.8 Hz, 2H; ; -CH2CH2CONH-), 3.66 (s, 2H; -
CH2OH), 3.78 (d, J= 12.1 Hz, 2H; -CCH2O-), 3.86 (d, J= 11.9 Hz, 2H; -CCH2O-), 4.66 (d, J= 2.6 Hz, 2H; -
OCH2CCH) and 6.39 (s, 1H; -NH-) ppm. 
13C NMR (100.6 MHz, CDCl3): δ= 19.90, 26.88, 29.12, 31.05, 






Synthesis of acetylene monomer (15): Compound 14 (48.7 g, 163 mmol), DMAP (4.0 g, 33 mmol) and 
TEA (27 ml, 195 mmol) were dissolved in DCM (230 ml) and placed on ice. Succinic anhydride (22.8 g, 
228 mmol) was added in portions and the reaction was stirred overnight. Proton NMR confirmed the 
total consumption of 14 (δ= 3.66 ppm, -CH2OH) and the reaction was quenched by addition of 
distilled water (200 ml). The crude reaction mixture was extracted with a weak acid (5X 300 ml, 10% 
w/v NaHSO4) and brine (5X 300 ml), whereupon the organic phase was dried with MgSO4, filtered to 
remove the solids and evaporated to yield the product (44.7 g, 69%, 100% purity by NMR). 
 
1H NMR (400 MHz, CDCl3): δ= 1.33 (s, 3H; -CH3), 1.40 (s, 3H; -CH3), 2.44 (t, J= 6.8 Hz, 2H; -
CH2CH2CONH-), 2.47 (t, J= 2.5 Hz, 1H; Act), 2.60-2.63 (m, 6H; -CH2-), 3.74 (d, J= 12.2 Hz, 2H; -OCH2-), 
4.12 (d, J= 12.1 Hz, 2H; -OCH2-), 4.41 (s, 2H; -CCH2OCO-), 4.61 (d, J= 2.2 Hz, 2H; -CH2CCH), 6.27 (s, 1H; 
-NH-) and 9.60 (s, 1H; -OH) ppm. 13C NMR (100.6 MHz, CDCl3): δ= 23.00, 23.60, 28.63, 28.83, 30.71, 

































































Synthesis of acetylene monomer anhydride (16): Compound 15 (44.7 g, 112 mmol) was dissolved in 
DCM (80 ml). DCC (11.5 g, 56 mmol) was dissolved in DCM (10 ml) prior to addition to the reaction 
mixture and left with stirring overnight. The precipitated dicyclohexylurea was removed by filtration 
and the solvent was evaporated to yield the product (30.0 g, 68%, 90% purity by NMR). 
 
1H NMR (400 MHz, CDCl3): δ= 1.33 (s, 6H; -CH3), 1.40 (s, 6H; -CH3), 2.41 (t, J= 6.8 Hz, 4H; -
CH2CH2CONH-), 2.46 (t, J= 2.3 Hz, 2H; Act), 2.59 (t, J= 6.7 Hz, 4H; -CH2CH2CONH-), 2.63 (t, J= 6.6 Hz, 
4H; -OCOCH2CH2COO-), 2.75 (t, J= 6.2 Hz, 4H; -OCOCH2CH2COO-), 3.77 (d, J= 11.8 Hz, 4H; -OCH2-), 
4.07 (d, J= 12.1 Hz, 4H; -OCH2-), 4.45 (s, 4H; -CCH2OCO-), 4.61 (d, J= 2.0 Hz, 4H; -CH2CCH) and 6.06 (s, 
2H; -NH-) ppm. 13C NMR (100.6 MHz, CDCl3): δ= 22.61, 24.05, 28.25, 28.79, 30.00, 30.70, 51.91, 
52.78, 62.34, 63.34, 74.92, 77.19, 77.44, 98.57 ((CH3)2COO-), 168.07 (-COOCO-), 171.31 (-COO-), 










2.2.4.2   Preparation of Dex-azide conjugate 
The azide anhydride (O(COCH2CH2CH2CH2CH2N3)2) used for this synthesis was kindly provided by 
research associate Yvonne Hed (KTH, Stockholm, Sweden). For the full NMR assignment of 
dexamethasone (Dex) the reader is referred to the literature (Liu et al. 1995). The 1H NMR 
assignment of the product will only consider effected shifts and compare those with corresponding 


















































Synthesis of Dex-N3 (17): Dex (6.9 g, 17.6 mmol) and DMAP (430 mg, 3.5 mmol) were dissolved in 
tetrahydrofuran (THF; 150 ml) and placed on ice. A solution of the azide anhydride (purity: 94 wt% by 
NMR, 7.2 g, 22.8 mmol) in THF (20 ml) was slowly dripped into the reaction solution, which was 
always kept in an argon atmosphere. The reaction was followed by TLC (80% EtOAc/20% Hep) and 
quenched with distilled water (20 ml) when Dex was consumed (Rf ≈0.6). THF was evaporated and 
replaced by DCM (200 ml) upon two phases were formed. The organic phase was purified by 
extraction with a mild base (4X 50 ml, 10% w/v Na2CO3) and a weak acid (4X 50 ml, 10% w/v 
NaHSO4), dried with MgSO4, filtered to remove the solids and evaporated to yield the product, which 
was further purified by gradient (EtoAc/Hep) flash chromatography to obtain the product (1.6 g, 17%, 
100% purity by NMR). 
 
1H NMR (400 MHz, DMSO-d6) for Dex: δ= 3.96 (dd, J= 13.4 and 5.8 Hz, 1H; -CH2OH), 4.41 (dd, J= 13.4 
and 5.9 Hz, 1H; -CH2OH) and 4.59 (t, J= 5.8 Hz, 1H; -CH2OH) ppm. 
1H NMR (400 MHz, DMSO-d6) for 









2.2.4.3   Preparations of First Generation Linear PEG-Dex Conjugate 
Synthesis of PEG-G1-2Act-Acet (18): Linear 10PEG-2OH (30 g, 6.0 mmol OH), acetylene monomer 
anhydride (16; 9.4 g, 12 mmol), DMAP (147 mg, 1.2 mmol) and pyridine (4.8 mg, 0.06 mmol) were 
dissolved in DCM (100 ml) and left on stirring overnight. The reaction was followed by 13C NMR (δ= 
168.07 ppm; -COOCO-) and if 16 was consumed an additional equivalent/OH was added. This was 
repeated twice to complete the reaction. The solvent was evaporated and the product redissolved in 
THF prior to precipitation in cold diethyl ether. The precipitation was repeated once more to yield 
the product (30.4 g, 94%). 
 
1H NMR (400 MHz, CDCl3): δ= 1.31 (s, 6H; -CH3), 1.40 (s, 6H; -CH3), 2.45 (t, J= 2.4 Hz, 2H; Act), 4.14-
4.18 (m, 8H; -OCH2CH2OCO- and -COCH2C-), 4.42 (s, 4H; -CCH2OCO-) and 4.60 (t, J= 2.2 Hz, 4H; -
CH2CCH) ppm. 




























63.30, 63.75, 68.68, 70.25 (PEG), 74.88, 77.19, 98.39 ((CH3)2COO-), 171.44 (-COO-), 171.63 (-COO-), 








Synthesis of PEG-G1-2Act-4OH (19): Compound 18 (30.4 g, 2.8 mmol) was dissolved in MeOH (200 
ml) and the acidic resin DOWEX 50W-X2 was added to the solution. The solution was heated to 30° C 
and stirred overnight. The deprotection was followed by 1H NMR (disappearance of δ= 1.31 and 1.40 
ppm). Since deprotection was incomplete the temperature was increased to 35° C and 
supplementary DOWEX resin was added. To drive the deprotection to completion the resin was 
removed by filtration and the solvent evaporated followed by continued deprotection with fresh 
MeOH (250 ml) and DOWEX resin at 35° C overnight with stirring. The resin was removed by filtration 
and the solvent evaporated prior to precipitation from THF into cold diethyl ether to yield the 
product (27.7 g, 92%). 
 
1H NMR (400 MHz, CDCl3): δ= 2.47 (t, J= 2.4 Hz, 2H; Act), 4.17 (t, J= 4.6 Hz, 4H; -OCH2CH2OCO-), 4.24 









Synthesis of PEG-G1-2Act-4Ac (20): Compound 19 (3.8 g, 1.4 mmol OH), TEA (394 μl, 2.8 mmol) and 
hydroquinone (catalytic amount) were dissolved in DCM (40 ml) and placed on ice while kept in 
argon atmosphere. AcCl (232 μl, 2.8 mmol) was separately dissolved in DCM (20 ml) and slowly 
added to the reaction solution from a dripping funnel, the reaction was then left overnight on 
























































value ~1 kDa). Insolubilities were removed by filtration and the solution was freeze dried prior to 
precipitation from THF into cold diethyl ether to yield the product (1.2 g, 31%). 
 
1H NMR (400 MHz, CDCl3): δ= 2.44 (t, J= 2.2 Hz, 2H; Act), 4.46 (d, J= 11.4 Hz, 4H; -CCH2OCOCHCH2), 
4.56 (d, J= 9.8 Hz, 4H; -CCH2OCOCHCH2), 4.67-4.68 (m, 8H; -CH2CCH and -CCH2OCOCH2CH2-), 5.39 (dd, 
J= 10.3 and 1.3 Hz, 4H; Accis), 6.12 (dd, J= 17.3 and 10.5 Hz, 4H; Ac) and 6.43 (dd, J= 17.2 and 1.3 Hz, 









Synthesis of PEG-G1-2Dex-4Ac (21): Compound 20 (2.29 g, 420 μmol acetylene groups; Act) and Dex-
N3 (12; 268 mg, 504 μmol) were dissolved in THF (55 ml). Sodium ascorbate (166 mg, 838 μmol) and 
copper sulphate (105 mg, 421 μmol) were dissolved separately in distilled water (1 ml respectively) 
and added to the reaction mixture. Additional distilled water (1 ml) was added to keep the solution 
clear. The reaction was followed by 1H NMR (δ =4.67-4.68 ppm) and when compound 20 was 
consumed the solution was diluted with THF (200 ml) and filtered to remove insolubilities. THF was 
evaporated and the solution diluted with water prior to freeze drying. The crude product was 
redissolved in THF (200 ml) and filtered through a column of activated neutral Al2O3 to remove the 
copper. The column was washed with DCM (100 ml) and the combined organic phases were removed 
by evaporation. The product was further purified by precipitation from THF (35 ml) and DCM (3 ml) 
into cold diethyl ether (250 ml) to yield the product (1.7 g, 68%). 
 






















































2.2.4.4   Preparations of First Generation 4-armed PEG-Dex Conjugate 
Synthesis of PEG-4arm-G1-4Act-Acet (22): Star shaped 10PEG-4OH (10.0 g, 4.0 mmol OH), the 
acetylene monomer anhydride (16; 6.9 g, 8.8 mmol), DMAP (98 mg, 0.80 mmol) and pyridine (3.2 ml, 
40 mmol) were dissolved in DCM (70 ml) and stirred overnight. The reaction progress was followed 
by matrix-assisted laser desorption ionisation mass spectroscopy (MALDI) and 13C NMR (δ =168.07 
ppm; -COOCO-). An additional amount of compound 16 (2 eq/OH) was added after the first night and 
both compound 16 (2 eq/OH) and DMAP (0.2 eq/OH) were added after the second night. The volume 
was evaporated and the crude product redissolved in toluene prior to precipitation in cold diethyl 
ether. The precipitation was repeated once to yield the product (3.5 g, 30%, 91% purity by NMR). 
 
1H NMR (400 MHz, CDCl3): δ= 1.36 (s, 12H; -CH3), 1.45 (s, 12H; -CH3), 3.73-3.77 (m, 8H; -CCH2Acet), 
4.24 (d, J= 11.1 Hz, 8H; -CCH2Acet), 4.46 (s, 8H; -CCH2OCO-) and 4.64 (d, J= 2.4 Hz, (H; -CH2Act) ppm. 
13C NMR (100.6 MHz, CDCl3): δ= 22.40, 24.40, 24.47, 25.05, 25.36, 28.79, 28.86, 28.94, 51.98, 52.10 
52.97, 62.10, 63.89, 68.83, 70.38, 74.94, 98.56 ((CH3)2COO-), 171.62 (-COO-), 171.72 (-COO-), 172.23 



















































































Synthesis of PEG-4arm-G1-4Act-8OH (23): Compound 22 was deprotected according to the same 
protocol as for compound 18. 
 
13C NMR (100.6 MHz, CDCl3): δ= 28.79, 28.83, 30.61, 45.17, 51.83, 60.95, 62.19, 62.50, 63.68, 68.62, 
69.65, 69.99, 70.21, 70.61, 72.20, 74.98, 77.19, 171.63 (-COO-), 172.03 (-COO-), 172.19 (-COO-) and 













Synthesis of PEG-4arm-G1-4Act-8Ac (24): Compound 23 was acrylated according to the same 

























































































1H NMR (400 MHz, CDCl3): δ= 4.47 (s, 8H; -CCH2OCO-), 4.54 (s, 16H; -CCH2OAc), 4.66 (d, J= 2.3 Hz, 8H; 
-OCH2Act), 5.88 (dd, J= 10.3 and 1.3 Hz, 8H; AcCis), 6.12 (dd, J= 17.3 and 10.5 Hz, 8H; Ac) and 6.42 (dd, 












Synthesis of PEG-4arm-G1-4Dex-8Ac (25): Compound 24 (500 mg) was conjugated with Dex-N3 (17) 
using the same protocol as for compound 20 to yield the product (180 mg, 31%). 
 












































































































































































At the time for the volumetric swelling experiment compound 25 had undergone spontaneous 
crosslinking to some extent. Thus, the compound was redissolved in DCM, filtered and precipitated in 
ice cold diethyl ether. 
2.2.4.5   Preparations of Second Generations Linear PEG-Dex Conjugate 
Synthesis of PEG-G2-6Act-Acet (26): PEG-G1-2Act-4OH (19; 15.0 g, 5.62 mmol OH), the acetylene 
monomer anhydride (16; 13.2 g, 16.9 mmol), DMAP (137 mg, 1.12 mmol) and pyridine (4.5 ml, 55.8 
mmol) were dissolved in DCM (100 ml) and left on stirring overnight. Complete reaction progress was 
confirmed by 13C NMR (δ= 168.07 ppm). The solvent was evaporated and the crude product 
redissolved in THF prior to precipitation in cold diethyl ether. The precipitation was repeated once to 
yield the product (15.8 g, 92%, 86% purity by NMR). 
 
1H NMR (400 MHz, CDCl3): δ= 1.39 (s, 12H; -CH3), 1.48 (s, 12H; -CH3), 3.78 (d, J= 11.4 Hz, 4H; -
CCH2OCO...Acet), 4.24 (d, J= 11.6 Hz, 4H; -CCH2OCO...Acet), 4.43 (s, 8H; AcetCCH2OCO-), 4.48 (s, 16H; 
-CCH2Acet) and 4.68 (d, J= 2.2 Hz, 12H; -OCH2Act) ppm. 
13C NMR (100.6 MHz, CDCl3): δ= 21.65, 22.19, 
24.12, 24.18, 24.76, 28.54, 30.52, 51.69, 52.49, 52.66, 57.49, 61.92, 62.21, 63.24, 68.52, 74.88, 74.94, 
98.18 ((CH3)2COO-), 98.25 ((CH3)2COO-), 171.40 (-COO-), 171.55 (-COO-), 171.62 (-COO-), 171.91 (-











Synthesis of PEG-G2-6Act-8OH (27): Compound 26 (15.4 g) was deprotected following a similar 
protocol as for compound 18, with the difference that the deprotection was restarted twice and the 
temperature was slightly elevated. The reaction mixture was heated to 35° C overnight and increased 
to 40 ° C for a few hours to ensure full deprotection. Precipitation yielded the product (12.4 g, 82%, 







































































1H NMR (400 MHz, CDCl3): δ= 4.29 (s, 8H; -CH2CCH2OH), 4.40 (s, 4H; -CCH2OCO...PEG), 4.42 (s, 8H; -












Synthesis of PEG-G2-6Act-8Ac (28): Compound 27 (12.0 g) was acrylated following a similar protocol 
as for compound 19, but no precipitation was needed after dialysis to obtain the pure product. (11.1 
g, 89%, ~100% purity by NMR) 
 
1H NMR (400 MHz, CDCl3): δ = 4.67 (d, J= 2.3 Hz, 12H; -OCH2Act), 5.89 (dd, J= 11.0 and 1.1 Hz, 8H; 
AcCis), 6.12 (dd, J= 17.3 and 10.5 Hz, 8H; Ac), 6.26 (s, 2H; -NH-), 6.28 (s, 4H; -NH-) and 6.43 (dd, J= 17.3 











Synthesis of PEG-G2-6Dex-8Ac (29): Compound 28 (2.0 g) was conjugated with Dex-N3 (17) in the 
presence of hydroquinone (catalytic amount), but otherwise using the same protocol as for 
























































































































































2.3   Atorvastatin 
Isolation of Atorvastatin (30): Lipitor tablets (n =20, 1.6 g atorvastatin; At; obtained from Merck) 
were pulverised and soaked in THF (350 ml) and water (5 ml) overnight prior to Soxhlet extraction 
(85 cycles). The solvent was evaporated and the crude extract loaded to silica (3 g) by evaporating 
the solvent from a chloroform mixture of the product and silica. The product/silica mixture was then 
loaded to a column packed with silica (10 g) in Hex which was washed with an increasing gradient of 
EtOAc in Hex. Ring closed At eluted at 50% and ring open At at 70%. All fractions containing ring open 
At (TLC Rf ≈0.7, 100% EtOAc) were pooled and the solvents co-evaporated with chloroform. The 
product was further dissolved in EtOH (15 ml), filtered and precipitated in cold diethyl ether (150 ml) 
to yield the product (248 mg, 16%). 
 
ESI-MS of compound 30: found (calculated, assigned) m/z= 559 (559.3, At + H+), 581 (581.2, At + Na+), 







































































































































































Synthesis of AtAc (31): At was acrylated according to the same protocol as for compound 5. 
 
2.4   General Procedures 
2.4.1   Dendritic Synthesis 
The assembling of the dendritic structures were based on a previously reported method (Malkoch et 
al. 2006). Only the key 1H NMR shifts are given for the drug conjugate and the dendritic compounds, 
normally terminal protons for which the shifts were changed during the actual or following reaction. 
13C NMR peaks are reported when available. 
 
2.4.2   DOWEX Purification 
The DOWEX resin was heated (45 ° C) in MeOH and collected on a filter. This procedure was repeated 
until the filtrate was colourless. 
 
2.4.3   NMR Analysis 
All nuclear magnetic resonance (NMR) spectra were recorded on a Varian spectrometer (300 MHz) 
except for the dendritic compounds for which a Bruker spectrometer (400 MHz) was used instead. 
 
2.4.4   mHPLC Analysis 
RaAc (5), RaMonoIAE (6a) and RaDiIAE (6b) were analysed with high pressure liquid chromatography 
(HPLC) on an Agilent 1200 series with respect to purity. The samples were loaded (5 μl, 1 mg/ml 
MeOH), separated into their constituents on a Jupiter C18 column (dimensions: 250 x 4.6 mm, 
porosity: 300 Å, particle size: 5 μm) from Phenomenex using a linear gradient of MeCN in distilled 
water (0-100% in 35 min, 0.7 ml/min) and detected with a diode array detector. The data was 























2.4.5   MS Analysis 
The molecular weights of RaAc (5), RaMonoIAE (6a) and RaDiIAE (6b) were confirmed by mass 
spectrometry (MS) on a Waters API Q-TOF Ultima mass spectrometer. The samples were dissolved in 
MeCN, diluted with 50% MeCN in water to 20 μg/ml and introduced (2 μl) to the MS using a Waters 
UPLC pump at a flow rate of 0.2 ml/min in a mixture of MeCN and 0.1% formic acid (80:20). The 
samples were ionised by electro spray ionisation (Baeyens et al.) in the positive mode (capillary 
voltage: 3.5 kV, cone voltage: 35, RF1: 40, source temperature: 100 °C, desolvation temperature: 350 
°C, desolvation gas flow: 350 l/h and cone gas flow: 50 l/h). Data was acquired at a mass/charge 
window of 300-1500 and processed with the “Masslynx 4.1” software. Only peaks with an intensity of 
1% or more of the respective main peaks are reported except for Ra for which all peaks are reported. 
 The amount of mono-, di- and tri-substitution of compound 5 was quantified by 
separating the crude reaction mixtures on an Xbridge C18 column (dimensions: 50 x 2.1 mm, Waters) 
in line with the ESI-MS system. The substituted compounds were washed out from the column by an 
increasing gradient of MeCN in 0.1% formic acid (20-100% in 12 min, 0.35 ml/min), quantified by UV 
absorption at 280 nm and assigned by ESI-MS. 
 
2.4.6   MALDI Analysis 
Matrix-assisted laser desorption ionisation time-of-flight mass spectroscopy (MALDI) was initially 
used to identify drug-PEG conjugates. The analyses were performed on a Voyager DE PRO mass 
spectrometer fitted with delayed extraction (PerSeptive Biosystems) and operated by the PerSeptive 
Biosystems Time-of-Flight Mass spectrometer software (version 4.51). Samples were dissolved in 
MeOH (10 mg/ml) and mixed in a 1:1 ratio with a freshly prepared matrix solution (α-Cyano-4-
hydroxycinnamic acid, 10 mg/ml in 50% MeCN and 50% H2O), 1μl was then applied to the plate 
which were inserted into the instrument and analysed in the linear mode. The obtained data were 
processed with PerSeptive GRAMS/32 software (version 4.14). 
 
2.4.7   Phosphate Buffered Saline 
Two different buffers were used throughout the gel work, both with a molarity of 150 mM and iso-
osmotic with blood. Phosphate buffered saline formula 1 (PBS-1) was used as supernatant during the 
swelling and drug elution experiments and phosphate buffered saline formula 2 (PBS-2), which has a 
higher buffering capacity than PBS-1, was used as solvent during gelling through conjugate addition. 
 PBS-1 was prepared by dissolving disodium hydrogen phosphate (Na2HPO4·12H2O, 
2.89 g, 8.1 mmol), potassium dihydrogen phosphate (KH2PO4, 0.20 g, 1.5 mmol), potassium chloride 














 PBS-2 was prepared by mixing solution A (65 ml), solution B (435 ml) and solution C 
(500 ml). Solution A: sodium dihydrogen phosphate (NaH2PO4·2H2O, 2.34 g, 15.0 mmol, 100 ml). 
Solution B: disodium hydrogen phosphate (Na2HPO4, 10.65 g, 75.0 mmol, 500ml). Solution C: sodium 
chloride (NaCl, 4.5 g, 77.0 mmol, 500 ml). All solutions were made in deionised water. 
 
2.4.8   Gel Formation 
The synthetic approaches were divided into categories referring to the main structure of the involved 
compounds. The categories (main structure) are; RaX-d4 (RaAc/IAE, 4-armed PEG carrier), RaX-d2 
(RaAc/IAE, 2-armed PEG carrier), RaDiIAE (RaDiIAE, no carrier), G1 (first generation, 2-armed 
backbone), 4arm (first generation, 4-armed backbone) and G2 (second generation, 2-armed 
backbone). 
The elution experiments included three gel formulations; “Bound” gels made by 
crosslinking compounds containing covalently attached drug, “Trapped” gels made by crosslinking 
the corresponding drug deficient compounds in the presence of free drug (equivalent to the amount 
in the corresponding “Bound” formulation) captured within the gel network and “Blank” gels made 
by crosslinking the corresponding drug deficient compounds. 
 
The multi-arm building blocks for the RaX-d4 and RaX-d2 categories were dissolved at a nominal 
concentration of 200 mg/ml and the following addition of crosslinker and RaPEG conjugate diluted 
these solutions to different degrees. 
 
The concentrations of building blocks for the G1, 4arm and G2 categories were obtained by 
considering solubility, amount of initiator, irradiation time and comparability between the gel 
categories.  
 
2.4.8.1   Photo-Polymerisation 
20PEG-8Ac (1; 65.3 mg) was dissolved in PBS-2 (170 μl), followed by addition of Ra (170 μl of 2.8 mg 
in 170 μl EtOH) and 2,2-dimethoxy-2-phenylacetophenone (DMPA; 29 μl of 4.7 mg in 2.0 ml N-
vinylpyrrolidone; NVP; 1 mol% DMPA and 1000 mol% NVP regarding Ac groups). Gels (100 μl, n =3) 
were formed from the pregel solution at a final concentration of 18% (mass of solids over added 
volume of PBS-2) and gelling occurred when irradiated by UV light (mercury lamp, 100 W) at a 
distance of 15 cm for 6 minutes. 
 Control gels were made by UV irradiation of; 1 (20%), a mixture of 1 and DMPA (1 














2.4.8.2   Mono-functional Approach, RaMonoX Method 1 
The multi-acrylate compound 20PEG-8Ac (1) was dissolved (200 mg/ml PBS-2) and individual PBS-2 
solutions of the crosslinker compound 10dPEG-4SH (4; 7 SH/10 Ac) and either RaAc-dPEG-3SH (7) or 
RaIAE-dPEG-3SH (8) were added at a loading density of 1 Ra/10 Ac. For “Trapped” gels a Ra solution 
(1 Ra/10 Ac, 20 μl EtOH) replaced the solutions of 7 and 8. The “Blank” gels were made of compound 
1 and 4 only (stoichiometric relation). Gels (50 μl each, n =3) were formed from the pregel solutions 
at a final concentration of 20-22% (mass of solids per added volume of PBS-2) and gelling occurred 
during 45 minutes incubation (37° C, 100% relative humidity). 
 
2.4.8.3   Mono-functional Approach, RaMonoX Method 2 
The multi-vinyl sulphone compound 20PEG-8VS (2) was dissolved (200 mg/ml PBS-2) and solutions of 
either RaAc-dPEG-SH (9; 20 μl PBS-2) or RaIAE-dPEG-SH (10; 20 μl PBS-2) were added at a loading 
density of 1 Ra/10 VS. The mixtures were incubated (37° C) for 20 minutes in closed containers prior 
to addition of the 2dPEG-2SH crosslinker compound (3; 9 SH/10 VS, 82 mg/ ml PBS-2). For “Trapped” 
gels a Ra solution (1 Ra/10 VS, 20 μl EtOH) replaced the solutions of 9 and 10 and also the “Trapped” 
pregel mixtures were incubated (37° C) for 20 minutes in closed containers prior to addition of the 
2dPEG-2SH crosslinker compound (3; stoichiometric ratio, 80 mg/ ml PBS-2). “Blank” gels were made 
of compound 2 and 3 only (stoichiometric ratio, PBS-2). Gels (100 μl each, n =3) were formed from 
the pregel solutions at a final concentration of 13-14% (mass of solids per added volume of PBS-2) 
and gelling occurred during 40 minutes incubation (37° C, 100% relative humidity). 
 
2.4.8.4   Mono-functional Approach, RaDiIAE 
Ra-diIAE (6b; 6.9 mg, 11.0 μmol IAE) was dissolved in MeCN (140 μl) and a solution of 10dPEG-4SH (4; 
400 mg/ml 0.1 M NaHCO3, 70 μl, 11.0 μmol SH) was added. Gels (50 μl each, n =3) were formed from 
the pregel solution in sealed containers at a final concentration of 17% (weight of solids over volume) 
and gelling occurred during 18 hours incubation (37° C). 
 
2.4.8.5   Dendritic Approach, Conjugate Addition 
PEG-G1-2Act-4Ac (20) or PEG-G1-2Dex-4Ac (21) were individually dissolved in PBS-2 and mixed with a 
PBS-2 solution of the crosslinker compound 10nPEG-4SH (stoichiometric ratio of thiol to Ac groups). 
For gels containing trapped Dex a solution (20 μl THF) of the unmodified drug (equivalent to the 
amount of covalently incorporated drug) replaced 21. Gels (50 μl each, n =3) were formed from the 
pregel solutions at a final concentration of 19% (weight of solids over added volume of PBS-2) and 














2.4.8.6   Dendritic Approach, Thiol-ene Addition 
 PEG-G1-2Act-4Ac (20), PEG-G1-2Dex-4Ac (21), PEG-4arm-G1-4Act-8Ac (24), PEG-4arm-G1-4Dex-8Ac 
(25), PEG-G2-6Act-8Ac (28) or PEG-G2-6Dex-8Ac (29) were individually dissolved by addition of 
separate THF solutions of the photo initiator Irgacure 2959 (5 or 10 mol% of the Ac groups) and the 
crosslinker compounds 2dPEG-2SH (3) or 10nPEG-4SH (stoichiometric ratio of thiol to Ac groups). For 
gels containing trapped Dex an additional THF solution (20 μl) of the unmodified drug (equivalent to 
the amount of covalently incorporated drug) was also added. Gels (15-25 μl each, n =3) were formed 
from the pregel solution at a final concentration of 38-69% (weight of solids over added volume of 
THF) and gelling occurred when irradiated by UV (ultraviolet) light (mercury lamp, 100 Watt) at a 
distance of 15 cm for 2 minutes. 
 
A side effect of the UV irradiation was a substantial evaporation of solvent as noticed by low gel 
weights (WGel), which in turn resulted in increased swelling ratios (WSwollen/WGel) compared to the 
conjugate addition gels. To minimise the evaporation effect the irradiation time was kept short. But, 
by decreasing the irradiation time the concentration of pregel compounds and initiator must be 
increased. 
 
The protocol was developed by carefully balancing the needs of a short irradiation time with the 
demands of a low concentration of both pregel compounds (similar to the conjugate addition gels) 
and initiator. Thus, the concentrations of building blocks were not equal for the three dendritic 
categories (38, 69 or 50% respectively) which are higher than for the mono-functional approach 
(20%). 
 
2.4.9   Drug Elution 
The formed gels (n= 3) were weighed, individually immersed in PBS-1 (2 ml, pH 7.4) and placed in an 
incubator (37° C) for swelling and drug elution. At regular intervals the supernatant was replaced by 
fresh buffer and at the same time the swollen gels were carefully blotted and weighed. The collected 
supernatant was diluted with EtOH (1:1), the absorbance (λRa= 279 nm and λDex= 241 nm) read in a 
spectrophotometer and the amount of released drug calculated using a standard curve made from 
serial dilutions of a PBS-1/EtOH (1:1) solution of respective drug. Supernatant from the “Blank” gels 
(n =3, pooled) were used as background readings for every drug eluting experiment except for gels 














 The gel end points were considered to be reached when supernatant could no longer 
be replaced because of a too substantial degradation. The remaining amount of covalently attached 
drug was forced to be released by treating the gels with NaOH (1 ml, 1 M). 
 
The theoretical drug content (mg /g gel), for the different gel formulations, was calculated using the 
weighed amount of drug-carrier conjugate compound, the molecular weight of the drug in relation to 
the drug-carrier conjugate compound and the measured volumes in each step of the mixing 
procedure. The calculated amount (mg drug/gel) was subsequently divided by the measured gel 
weight (average of 3; before swelling) of respective formulation. 
 
2.4.10   Determination of pH dependence of gel formation 
Gels (n =1) were made by crosslinking 20PEG-8Ac (1; 200 mg/ml) with 2nPEG-2SH in a Ac:SH ratio of 
1:1 at a final concentration of 10% in PBS-2 of different pH (adjusted with dilute hydrochloric acid). 
Gelling was assessed to occur when the gel solutions were sufficiently solidified to be removed in one 
piece from the support. 
 
2.4.11   Curve Fitting 
The curve fitting application in Excel (Microsoft Office) was used to fit linear curves to the obtained 
elution data, either directly or after processing the data with any of the following equations. Neither 
the origin nor data after forced release with NaOH were used for the calculations and the Y-axis 
intersection of the fitted curves was not guided through zero. 
 To assign degradation as the primary release mechanism the Hixson-Crowell (Shoaib et 







The rate constant for the Hixson-Crowell rate equation is described by kHC. To differentiate between 
diffusion and swelling as the primary release mechanism the Korsmeyer-Peppas equation (Siepmann 






















The structural/geometric constant for a particular system is described by k and n is the release 
exponent. The experimentally obtained n-value is characteristic for the release mechanism and for a 
cylindrical drug eluting matrix an obtained value of (describes the release by); n =0.45 (diffusion), 
0.45 < n < 0.89 (a mixture of diffusion and swelling), n =0.89 (swelling).  
Zero order release was confirmed by fitting obtained data to the zero order rate 
equation (Equation 4). 
 
tkQrem 0  (4) 
 
Qrem is the remaining release at time t and k0 is the zero order rate constant expressed in units of 
cumulated release per time. First order release was confirmed by fitting obtained data to the first 
order rate equation (Equation 5). 
 
tkQQrem 10lnln   (5) 
 
Q0 is the total cumulated amount of released drug and k1 is the first order rate constant. In case 
exponential release was obtained an online curve fitting programme was used to find a proper 
equation for the profile (www.ZunZun.com). 
 
The following plots were made for the “Trapped” formulations (to establish the release mechanism); 
cube root of normalised remaining amount of drug versus elution time (degradation controlled 
release), logarithm of normalised cumulated release versus logarithm of elution time (diffusion or 
swelling controlled release) and natural logarithm of normalised remaining amount of drug versus 
elution time (first order release and k1). To calculate elution curves with first order release kinetics a 










The following plots were made for the “Bound” formulations (to establish the release mechanism); 
cumulated release versus elution time (zero order release) and natural logarithm of normalised 




















The fraction of the total squared error (commonly known as the R2-value) was used to determine 
whether the applied curve fittings were significant or not and for a R2 >0.95 an applied curve was 
considered significant. In contrast, if none of the applied curves fitted, the elution was considered to 
be of burst character. 
 
2.4.12   Swelling 
The swelling ratio Q for a hydrogel is normally defined as Vswollen/Vdried but in this work it was decided 
for several reasons to mainly use a mass and wet gel based swelling ratio instead (Wswollen/Wgelled).  
The primary reason to use the mass instead of the volume is because it is possible to 
follow the swelling trend for a longer period of time by weighing the gels in air only, since this is still 
possible when a gel is too degraded to be weighed in EtOH, which is necessary to establish Vswollen. 
Additionally, since the gels contain > 90% water their mass and volume are nearly identical (not 
shown). 
The reason for using the mass of formed gels, instead of dried gels, as the 
denominator has a practical background, since it mirrors the degree of swelling compared to the 
formed gel and not to its dry content, which is an important parameter for in vivo applications.  
Additionally, weighing the same gels repeatedly instead of drying three gels for each data point, 
which is needed to calculate the volume, is an efficient way to economise a limited amount of 
material. 
 
2.4.13   Volume Determination 
In order to further calculate crosslink densities the volume of a limited number of gels were also 
measured. 
 
Gels (n= 2 or 3 for each data point) were formed, immersed in buffer and placed in an incubator in 
the same manner as for the drug elution experiments describe above. At the same time points as for 
the respective drug elution experiment (including day 0) the supernatant was either changed or the 
gels were weighed both in air and EtOH, dried (60° C) overnight and then weighed in air and EtOH 
again. The volume of the just gelled (Vg), swollen (Vs) and dried (Vd) gels was calculated from the 
respective mass according to Equation 6 and further used for the calculations of crosslink densities. 
 
































Owing to limited resources of the dendritic compounds volumetric swelling of the G1 category was 
omitted and only duplicates were made for the 4arm and G2 categories. 
 
2.4.13.1   Calculation of Crosslink Density 
Equation 7 was used to calculate average molecular mass between crosslinks, Mc (Andreopoulos et 
al. 1998). 
 
     (7)
 
 
The swelling data is represented by the u2,s and u2,r variables, which are the averaged volumetric 
ratios of dry gels over swollen and just gelled gels respectively. The constants are; Mn the molecular 
mass of the PEG building block, u (0.861 ml/g) the specific volume of the PEG building block before 
crosslinking, V1 (18.1 ml/mol) the molar volume of water and χ (0.426) the polymer-solvent 
interaction parameter for a PEG-water system. 
 
Equation 8 was used to calculate the average mesh size, ζ (Å), for the swollen hydrogels. The 
constants are; Cn (4.0) the characteristic ratio of PEG and l (1.48 Å) the bond length of the gel’s 
polymeric backbone. 
 
  (8) 
 
The experimental data is represented by αs and was calculated according to Equation 9. The number 
of bonds between two crosslinks n was calculated according to Equation 10 where Mc is the 
previously calculated average molecular weight between crosslinks and Mr (44 g/mol) is the 














Equation 3 and 4 involve several system specific constants which are experimentally and 
computationally obtained. For the calculations presented here the specific volume of the pregel 
compounds were roughly assumed to be equal to unmodified PEG and the polymer-solvent 
interaction was assumed to be equal to a PEG-water system. These estimations are particularly 

























presented as relative mesh sizes where the mesh size for swollen gels are normalised by the value of 
respective gel prior swelling. The compounds in the mono-functional approach, however, 
predominantly consist of the PEG carrier (> 90% by mass) and therefore the actual mesh sizes are 
shown in this case. 
 
2.4.14   Reporter Assays 
The activity of released drugs were determined via cell treatments and quantified by pre-fabricated 
reporter assay kits resulting in luciferase mediated luminescence, which was measured on a Veritas 
Microplate Luminometer (Turner Biosystems) using the Veritas software (version 2.0.5101). 
 
2.4.14.1   Rapamycin 
The protocol for Ra treatment of cells was adopted from a previously reported method (Yallapu et al. 
2008) and was implemented as follows: 
 Human aortic smooth muscle cells (Passage 3) were seeded in a clear 96-well plate 
with 104 cells per well in 100 μl sodium bicarbonate buffered MCDB medium with 10% fetal calf 
serum and left to attach for 6 hours at 37° C in a humidified atmosphere with 5% CO2. The medium 
was then replaced by 100 μl of sterile filtered medium-based treatment solutions containing either 
gel supernatant (10% v/v) or Ra (1-2000 μg/l). The Ra solutions were made from serial dilutions with 
medium of a stock solution (20 mg Ra/ml MeOH). All treatment solutions had a final concentration of 
10% v/v PBS-1 and 0.01% v/v MeOH. Cell deficient wells (Empty) were given the same treatment as 
cell containing wells (Cell) and were used as background readings for the calculations in Equation 11. 
On second day and every alternate day the medium was replaced by fresh medium without further 
addition of treatment. 
 Inhibition of cell proliferation was monitored on the 8th day by leaving the plate reach 
room temperature and adding a cell viability reagent (Promega, CellTiter Glo) that induces 
luminescence proportional to the amount of living cells. The assay reagent (100 μl) was added to 
each well, incubated (15 min, Troom) with shaking at regular intervals (1 min at t= 0, 5, 10 min) and 
placed in the luminometer (1 sec reading/well) where the luminescence was measured. 
 
      (11) 
 
The reduced cell proliferation resulting from Ra treatment is presented in terms of percent cell 
growth where the background luminescence for all treatments was subtracted prior to normalisation 
























2.4.14.2   Dexamethasone 
The protocol for determination of Dex activity in gel supernatants was adopted from a previously 
reported method (Wilson et al. 2002). The method is based on using a breast cancer cell line which is 
genetically transformed to induce luciferase expression upon binding of glucocorticoid receptor 
agonists, such as Dex and was implemented as follows: 
MDA-kb2 cells (Passage 3) were seeded in a white 96-well plate with 104 cells per well 
in 100 μl Leibovitz L-15 Hepes buffered medium with 10% fetal calf serum and left to attach for 6 
hours at 37° C in a humidified atmosphere. The medium was then replaced by 100 μl of sterile 
filtered treatment solution consisting of 1 ml buffer/medium/serum mixture plus 1 μl of either Dex 
containing PBS-1 supernatant, Dex dissolved in EtOH or pure solvent (PBS-1 or EtOH) and incubated 
at 37° C for 24 hours. Cell deficient wells (Empty) were given the same treatment as cell containing 
wells (Cell) and were used as background readings for the calculations in Equation 12. The plate was 
left to reach room temperature and treated with a luciferase reagent (100 μl/well; Promega), shaken 
(10 seconds) and immediately placed in the luminometer (1 sec reading/well) where the 
luminescence was measured.  
 
    (12) 
 
The Dex induced luciferase expression is presented in terms of fold induction (FI) where the 
background luminescence for all treatments was subtracted prior to normalisation by a sham 





























3   RESULTS and DISCUSSION 
 
he main goal of the work in this thesis was to obtain tailored and sustained drug delivery 
systems. To achieve such systems both mono- and di-functional PEG based approaches were 
embraced and developed. The synthesised compounds were used to form hydrogels, using either 
conjugate or thiol-ene addition, which were further evaluated with respect to their drug elution 
profile, swelling ratio and degradation rate. 
 
Ultimately, the aim is to use these hydrogel systems to improve post MI recovery by injecting the 
gels into the affected myocardium. The beneficial effect of such injection has previously been proved 
by our group (Dobner et al. 2009; Kadner et al. 2012) and is reviewed by Nelson et al. 2011). 
Furthermore, the aim with these gels is to represent a foundation for the further development of 
coatings to improve patency and to decrease restenosis of vascular grafts and stents.  
However, the focus in this thesis was to develop the chemistries for hydrogel 
platforms, from which the abovementioned aims can be achieved. Therefore, the evaluation of drug 
elution kinetics was limited to in vitro methods in PBS, which are previously well documented, as well 
as generally accepted in the literature as initial experiments prior evaluation in serum and in vivo 
(Alexis et al. 2004; Nuttelman et al. 2006; Wang, X. et al. 2006; Ito et al. 2007; Jo et al. 2009; LU et al. 
2011). 
 
The following results are presented together with relevant discussion, starting from the synthetic 
work and followed by gel formation and the characterisation thereof. 
 
3.1   Synthesis of Gel Building Blocks 
The synthesis of gel building blocks was the part of the thesis that presented the most opportunities 
for problem solving and also provided the most opportunities to develop new hydrogel concepts as 
presented here. 
 
3.1.1   Multi-arms 
The PEG acrylate multi-arm (20PEG-8Ac; 1) was obtained as a white powder in good yields (68%), 
which was slightly lower then previously reported (86%) by (Elbert et al. 2001). The lower yields are 
explained by a more extensive purification protocol compared to Elbert et al. (3 subsequent 
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by NMR and a high degree of Ac substitution was also confirmed by a gelling test with a 2-armed 
crosslinker where the gel point was reached within 5 minutes. 
The PEG vinyl sulphone multi-arm (20PEG-8VS; 2) was obtained in a low yield (32%) 
compared to previous reports (65%) by (Dobner et al. 2009), probably as a result of spontaneous 
crosslinking of the vinyl sulphone groups. The formation of solids during synthesis supports this 
assumption. A possible explanation for the occurrence of spontaneous crosslinking of αβ-
unsaturated double bonds in the synthesis of 2 but not for 1 could be the different polymer 
concentrations in the reaction medium. The concentrations during synthesis of 2 and 1 were 40 and 
17 mg/ml respectively. 
 
3.1.2   Crosslinkers 
In this work two different crosslinkers were used, one with built-in hydrolytic degradability (dPEG-SH) 
and the other without (nPEG-SH). The dPEG-SH crosslinkers were readily synthesised in one step and 
good yields were obtained (~90%) in the same range as previously reported (Nie et al. 2007). Their 
built-in degradability was verified by the degradation of gels formed with non-degradable crosslinks 
(Figure 14). 
 
Gels were formed by crosslinking 20PEG-8VS with either dPEG-SH or nPEG-SH (Figure 14, green 
plots). The former combination was too disintegrated for further measurements on day 18 while the 
latter showed no visible degradation by day 20, as assessed by a non-significant increase in post 
equilibrium swelling (23 ±3 to 26 ±1) and mesh size (156 ±15 to 169 ±8 Å). Since previous 
experiments in our laboratory (not shown), for gels made with the PEG-VS + nPEG-SH combination, 
did not indicate degradation while incubated for more than a year it was decided to only measure 










Figure 14: Swelling ratio and mesh size for gels formed by crosslinking either 20PEG-8Ac (1) 






















































Observed degradation of gels made from crosslinking 20PEG-8VS with either dPEG-SH or nPEG-SH 
followed the expected trend since the former crosslinker introduces hydrolytically degradable thio-









Figure 15: Gel-Gel crosslinks formed by reacting PEG-VS and dPEG-2SH or nPEG-2SH, 
respectively, red bonds are hydrolytically labile. 
 
When considering the gels made from crosslinking 20PEG-8Ac with either dPEG-SH or nPEG-SH 
(Figure 14, red plots) it was observed that the two gel formulations degraded within a similar time 
period (9 and 8 days, respectively). This observation is not in line with the expected outcome since 
the former crosslink contain four weakened esters while the latter contains only two (Figure 16). 
Therefore the nPEG-SH crosslinked gels should last longer than gels crosslinked by dPEG-SH. The 









Figure 16: Gel-Gel crosslinks formed by reacting PEG-Ac and dPEG-2SH or nPEG-2SH, 
respectively, red bonds are hydrolytically labile. 
 
For both multi-arms the gel formulations crosslinked by nPEG-SH displayed a much higher level of 
equilibrium swelling than the respective gels crosslinked by dPEG-SH. In theory the crosslink density, 
and hence the equilibrium swelling, should be similar for the two systems. The unexpected and 
elevated equilibrium swelling of gels crosslinked by nPEG-2SH may be explained by a low degree of 














the multi-arms, but without forming crosslinks. The presence of a considerable amount of this 
impurity was confirmed by 13C NMR (not shown) and a decreased crosslink density was verified by 
the calculated mesh sizes in Figure 14. 
 
3.1.3   Mono-functional Approach 
The mono-functional approach is a two-step method, which resulted in rapamycin (Ra) covalently 
pending from the hydrogel network. The method is referred to as “mono-functional” since one thiol 
of the dPEG-4SH or dPEG-2SH crosslinkers, which were used as drug carriers, was conjugated to Ra 
and the remaining thiols/thiol were used for gel incorporation. Thus, the same type of functionality 
was used for two purposes. 
 
The method development of the mono-functional approach includes valuable problem solving, 
therefore a summary is given. However, the summary is placed after the method presentation since 
the chemistry used during the problem solving is explained here. 
 
In the first step Ra was substituted with either Ac or IAE functionality in order to be susceptible to 
conjugate addition or nucleophilic substitution by the drug carrier. The hydroxyl groups of Ra were 
targeted for addition of these functional groups, but since there are three hydroxyl groups there is a 
possibility of several product combinations. Three of these combinations (mono-, di- and tri-
substituted Ra) were identified by TLC and liquid chromatography in combination with ESI-MS. In 
Table 2 the resulting substitution patterns from the reaction of Ra and 2, 4 or 6 equivalents of AcCl 
are shown. 
 
Table 2: Product compositions of crude RaAc products after reacting Ra and increasing 
equivalents of acryloyl chloride. Amounts are given in per cent. For the lowest excess of AcCl 
di- and tri-substitutions were not detected (n.d.). 
 Conversion Mono-substitution Di-substitution Tri-substitution 
2 eq 54 ~100 n.d n.d 
4 eq 100 18 67 15 
6 eq 100 10 38 53 
 
Using 2 equivalents of AcCl resulted in nearly 100% mono-substitution but the conversion was low 
(54%). Therefore the use of 4 and 6 equivalents were also investigated, resulting in complete 
conversions but also an increased amount of di- and tri-substitution. However, it was observed that 
the acrylation reactions were not very repeatable in terms of substitution degrees, possibly because 














precipitate. The formation of this precipitate was dependent on the addition method of AcCl, 
therefore AcCl was added drop wise in portions of two equivalents from a dilute solution until Ra was 
consumed, as verified by TLC. 
The consumption of reagents, by forming the precipitate, is believed to be the main 
reason for the need to use more than one eq of AcCl to form RaMonoAc. Another possible reason 
could be that the reaction conditions were not completely dry which results in the hydrolysis of AcCl. 
 
Mono- and di-substitution was also observed while synthesising Ra-IAE, but tri-substitution was 
never detected. The absence of tri-substitution is believed to originate from the substitution method 
since the carbodiimide coupling reagent is not as susceptible to nucleophilic attacks as the acid 
chloride used for acrylation is. Hence, the sterically hindered hydroxyl group on position 10 is not 
reactive towards carbodiimide coupling. 
 
According to the literature the group at position 40 (numbered positions are found in Scheme 10) is 
the most reactive, followed by the groups at position 28 and 10, respectively (Plattsburgh et al. 
1998). This is in agreement with expectations since the hydroxyl group at position 40 is least 
sterically hindered and the group at position 10 the most.  
In order to simplify the following synthesis steps and their analysis the mono-
substituted products, RaMonoAc (5) and RaMonoIAE (6a), were isolated at high purity (100% for 
both derivatives) but moderate yields (35% for 5 and 65% for 6a). The yield of 6a, however, was 
superior than previously reported (57%) by (Lee et al. 1998). The purity of 5 and 6a were confirmed 
by reversed phase HPLC analysis that showed only one signal peak for each compound (40.95 min for 
5 and 41.07 for 6a min). These peaks were slightly delayed in the hydrophobic column compared to 
pure Ra (37.64 min), a result from the exchange of a polar hydroxyl group to less polar Ac and IAE 
groups. The structural features of the derivatives were analysed by ESI-MS and the measured 
molecular masses agreed with the expected products. The assigned mass spectra of Ra and 6a are 











































Figure 17: ESI-MS spectra of Ra and Ra-MonoIAE (6a). Only peaks with intensity higher than 
1% of the main peaks are reported. The numbered Ra peaks correspond to the peaks 
denoted with a prime in the spectrum of 6a.  
 
Evidently Ra disintegrates to a large extent during ESI-MS analysis. Two main fragments (1 and 3), 
which in turn formed adducts with water (2, 4, 5 and 6), the intact drug in complex with ions (7 and 
8) and another cluster (9) were repeatedly occurring (Figure 17, upper spectrum). These Ra 
fragments are also present in a previously reported Ra spectrum (Rajender et al. 2010). The peaks in 
the Ra derivative spectrum agreed with the respective products and were assigned by adding the 
exact mass of the functional groups (54.0 Da for Ac and 167.9 Da for IAE) to each peak in the Ra 
spectrum (Figure 17, lower spectrum). 
 
Figure 18 shows the 1H NMR spectra of Ra, RaAc (5) and RaIAE (6a). As seen in the top spectrum Ra 
exhibits overlapping peaks from δ =0.5 to 6.5 ppm with only a few gaps. These peaks make it difficult 
to identify the shifts of effected protons during synthesis and efficiently cover new peaks of the 
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Figure 18: Stacked 1H NMR (300 MHz, CDCl3) spectra of rapamycin and its derivatives. 
 
According to McAlpine et al. the shifts of -CHOH- at position 40 are 3.37 and 3.35 ppm respectively, 
but there are also five other groups of peaks assigned for that range (δ= 3.33- 3.41) making it almost 
impossible to identify these protons without a proper investigation involving a range of 2D 
experiments (McAlpine et al. 1991). An aggravating fact is that rapamycin is a mixture of three 
isomers, of which two are conformational isomers about the amide bond, which induces further 
overlap of the peaks (Ricciutelli et al. 2006). Therefore NMR was not used for the analysis of Ra 
derivatives and conjugates. 
 
In the second step the RaAc and RaIAE derivatives were conjugated with dPEG-SH (3 or 4), which 
resulted in water soluble conjugates (at least 180 mg/ml). The reactions were carried out in a 
stoichiometric relation of X to SH groups, theoretically resulting in one drug attachment per carrier.  
 The amounts of Ra incorporation for RaAc-dPEG-3SH (9) and RaIAE-dPEG-3SH (10) 
were 79.8 and 66.6 mg/g product, respectively, which are close to the calculated value (80.9 mg Ra/g 
product) in case of both compounds (Table 3). 
 
Table 3: Experimentally determined rapamycin contents for the Ra-PEG conjugates. 
 RaAc-dPEG-3SH (9) RaIAE-dPEG-3SH (10) Calculated value 
Ra content [mg/g product] 79.8 66.6 80.9 
 
The Ra modification and subsequent PEGylation that make up the mono-functional approach is 
summarised in Scheme 10. 
Rapamycin 
Ra-MonoIAE  





























































Scheme 10: Overview of the “Mono-functional Approach” towards covalent rapamycin 
incorporation into gels. Note that the PEG-SH links are simplified and only show the terminal 
bond. 
 
Here follows a summary of the problem solving during method development of the mono-functional 
approach. 
 
The RaAc derivative was initially PEGylated with 2nPEG-2SH and the conjugate was analysed by 
MALDI, but only a single broad peak for the carrier at 2 kDa was detected with no trace of the 
expected product closer to 3 kDa. Inspired by the literature (Plattsburgh et al. 1998; Yu et al. 2005) 
an alternative coupling route was investigated using the RaIAE derivative. The PEGylated product, 
RaIAE-nPEG-2SH, was analysed by MALDI but not detected, again in favour of the non-conjugated 
carrier at 2 kDa. 
 To simplify the conjugation reactions and the following product analysis as much as 
possible the polymeric carrier was replaced by mercaptoethanol as a substitute for PEG-SH with only 
one repeating unit. The products from these model reactions, using both the RaAc and RaIAE routes, 
were successfully confirmed by ESI-MS. 
 
To overcome possible solvent effects resulting in a reduced availability of the reactive polymer 
terminals when conjugating RaX with 2nPEG-2SH, PEG-2SH of different molecular masses were 
synthesised. Since the protocol for synthesising nPEG-SH involves 3 steps (Hiemstra et al. 2007) of 
which the last was not successful (unpublished results), the one step esterification reaction for 
producing dPEG-SH was used instead. Hence, both RaAc and RaIAE were reacted with dPEG-2SH of 
various molecular masses. The conjugates were analysed by ESI-MS and MALDI and showed product 
peaks, but also a considerably amount of uncoupled dPEG-2SH. Formation of Ra conjugates with 
0.6dPEG-2SH and 0.9dPEG-2SH were confirmed by MS but were not water soluble, the conjugates 

















At this stage the opportunity to perform MALDI analysis in-house was given and it was soon obvious 
that the Ra-PEG conjugates were fragile and easily broke up when analysed with too high laser 
intensity on the MALDI. Nonetheless, by carefully tuning the intensity an intact conjugate could be 
monitored. However, compounds with high molecular mass, such as the 10dPEG-4SH, tend to give 
rise to broad and overlapping peaks, which in this case aggravate the distinction between the 












Figure 19: Overlaid MALDI spectra of 10dPEG-4SH (4) and RaIAE-dPEG-3SH (10). The laser 
intensity was 2270 units in both cases. 
 
To more clearly illustrate the break-up of conjugates an example of a lower molecular mass 
compound is used (RaAc + 2dPEG-2SH). The product contained a mixture of unreacted (2dPEG-2SH, 
2.2 kDa), mono-substituted (Ra-dPEG-SH, 3.2 kDa) and di-substituted (Ra-dPEG-Ra, 4.2 kDa) carrier 
(Figure 20). By successively increasing the laser intensities during MALDI the di-substituted Ra-dPEG-
Ra compound (lower spectra) first degraded into Ra-dPEG-SH (middle spectrum) and further into 

























Figure 20: Stacked MALDI spectra of Ra-dPEG-SH. The laser intensities (top to bottom) were 
3400, 2880 and 2780 units, respectively. 
 
The breakdown of conjugates suggests there is a fragile bond attaching the drug with the carrier. This 
is encouraging since the concept of controlled drug release in this work is based on the formation of 
a weakened ester bond. Hence, it was assumed that these bonds break during the rather harsh 
conditions that MALDI presents. This hypothesis is strengthened by the literature where the breaking 
of ester bonds during MALDI analysis was previously observed, thus making it a likely explanation for 
the product degradation in this work (Elandaloussi et al. 2006). 
 
3.1.4   Dendritic Approach 
The mono-functional approach as presented above results in the delivery of 1 drug molecule per PEG 
carrier. In order to obtain higher drug loading densities dendritic multi branched structures were 
developed, which allow for the delivery of 2, 4 or 6 drug molecules per PEG carrier. 
 
Only three building blocks (PEG, Dex-N3 and acetylene monomer anhydride) were used to assemble 
each of the three dendritic categories (G1, 4arm and G2). The methodology used to synthesise the 
building blocks and dendritic compounds is presented in the following text and regarding the 
dendritic compounds, only one example from each step in the successive build up procedure is 
presented. 
 
The preparations of the acetylene monomer anhydride (16) involved 6 reaction steps, which are 
previously published (Antoni et al. 2009). Therefore only the crucial reaction step where the 









































































Figure 21: 1H NMR (400 MHz, CDCl3) spectra of acetylene (14) and succinate (15) addition to 
acetonide protected trizma (11). 
 
The reaction scheme in Figure 21 shows the coupling of compound 11 and 13 where the anhydride 
has the possibility to react with both the hydroxyl and amine group. Since the amine is more prone to 
nucleophilic substitution the reaction at this position w s kinetically favoured by performing the 
reaction in an ice bath. The probability of having di-substitution was further decreased by using a 
deficit of the anhydride (0.8 eq) added slowly from a dilute solution.  
 To identify potential di-substitution of 14 the spectrum of compound 15 was used, 
since HA for di-substituted 14 and compound 15 would have a similar shift. The small peak denoted 
HA,Di (δ= 4.46 ppm) corresponds relatively well with HA of compound 15 (δ= 4.41 ppm) and by using 
the peak integrals a degree of mono-substitution for compound 14 higher than 98% was calculated. 
 
Dex-N3 (17) was obtained with a low yield (17%) due to a high extent of di-substitution. Dex has three 
hydroxyl groups; one primary (OHPrim), one secondary (OHSec) and one tertiary (OHTert). The main 
reaction product was formed via substitution at OHPrim and di-substitution occurred at OHPrim and 
OHSec, but no reaction was observed to take place at OHTert (Figure 22). To explain the high degree of 
di-substitution for the synthesis of 17 compared to the synthesis of 14 the reactivity of the respective 
starting material is used. Dex has three hydroxyl groups in slightly different environments and 
apparently the reactivity of OHPrim and OHSec is rather similar. The protected trizma on the other 
hand, has one amino group and one hydroxyl group where the former is the better nucleophile 

























































































1H NMR (400 MHz, DMSO-d6) spectra of Dex and Dex-N3 (17). 
 
Figure 22 shows how HA shifts downfield and OHPrim disappears for the mono-substituted product 
compared to Dex. For the di-substituted by-product there was an additional shift of the HB proton as 












H NMR (400 MHz, CDCl3) spectra of Dex-MonoN3 (17) and dex-DiN3. 
 
The acetylene monomer anhydride (16) was used for each generation growth in this work as 
depicted in Figure 24 for PEG-2OH (due to limited space and increased clarity only one arm is drawn 




























































Figure 24: 13C NMR (100.6 MHz, CDCl3) spectra showing the consumption of acetylene 
monomer anhydride (16) during the synthesis of PEG-G1-2Act-Acet (18). 
 
The reaction progress was followed by 13C NMR spectroscopy. As compound 16 was totally 
consumed (Figure 24, middle spectrum; detected by the disappearance of the anhydride carbonyl 
carbon CAnh), more of the compound was added. The lower spectrum in Figure 24 shows the purified 
final product. 
 
The following removal of acetonide protection groups was successful (yields >80%) and confirmed by 
1H NMR spectroscopy (Figure 25). However, the deprotection process often stagnated and the 
reaction needed to be restarted with fresh MeOH and Dowex resin for further progress. The halted 
reaction progress was assumed to be a result of reaching equilibrium with the released protection 














Figure 25: 1H NMR (400 MHz, CDCl3) spectra of PEG-G1-2Act-Acet (18) and PEG-G1-2Act-4OH 
(19). 






















































In Figure 26 the acrylation of PEG-G2-6Act-8OH (27) is shown and the protons of the attached 
acrylate group are marked HAc, HCis and HTrans respectively. For some of the acrylation reactions 
extensive homo-polymerisation occurred as detected by sticky deposits on the walls of the reaction 
vessel. According to Srinivasan et al. self-initiated homo-polymerisation of terminal alkane acrylate 
groups is likely to occur (Srinivasan et al. 2010), therefore hydroquinone was added to quench 
formation of radicals. However, homo-polymerisation occurred nonetheless for some of the 
acrylation reactions and lowered their yields drastically. 
In light of the spontaneous homo-polymerisation it would be preferred to perform the 
acrylation reaction as the last step, after incorporation of Dex, in order to only experience reduced 
yields by homo-polymerisation in one reaction step. Nonetheless, the acrylation reaction was 
performed before the Dex incorporation step since it was preferred to use the same batch of 

















Figure 26: 1H NMR (400 MHz, CDCl3) spectra of PEG-G2-6Act-8OH (27) and PEG-G2-6Act-8Ac 
(28). R is a general denomination and represents the bulk of the molecule. 
 
The triazole formation during Dex incorporation moved the shift of HA downfield as illustrated in 
Figure 27 for PEG-4arm-G1-4Dex-8Ac (24), while the change of HB shift was less pronounced. The HA 
shift of 24 is not included in the displayed range since it is part of a multiplet of several protons at δ= 
2.49 ppm. HB on the other hand is an isolated peak, slightly doubled by long range coupling to HA, 

































































Figure 27: 1H NMR (400 MHz, CDCl3) spectra of PEG-4arm-G1-4Act-8Ac (24) and PEG-4arm-
G1-4Dex-8Ac (25). 
 
This HDC click reaction is dependent on copper, added as Cu (Nie et al.)SO4 and reduced to Cu(I) by 
sodium ascorbate, to coordinate the alkyne and azide groups during the reaction progress (Hein et al. 
2008). To obtain biocompatible compounds the amount of copper was reduced since an excessive 
amount in the circulatory system leads to the development of various malfunctions (Wang, T. et al. 
2006). 
 
The dendritic compounds were built from the terminal of PEGs in order to obtain water solubility of 
the final products and to facilitate purification. However, the drug carrying compounds in the 4arm 
and G2 categories were difficult to precipitate, hence their yields were lower than for the G1 
category (G1 68%, 4arm 31% and G2 52%). Interestingly, these were also the only two compounds 
that were not water soluble. By considering the drug loading densities for the three dendritic 
categories (G1 2 Dex, 4arm 4 Dex and G2 6 Dex per 10PEG molecule) it was assumed that a too high 
loading density of Dex (>2 per 10PEG molecule) results in loss of water solubility of the PEG carrier. 
However, it is expected that the use of a bigger PEG carrier (>>10 kDa) would bring also the 4arm and 
G2 compounds into water solubility. 
 





























































































































































































































































































































































































































































































































3.2   Gel Formation Chemistries 
In this work a variety of multi-arm and crosslinker combinations were used. The gel points of these 
combinations (percent conversion where a sufficient amount of crosslinks are created to form a 
continuous gel network) were calculated with Equation 1 (Table 4). 
 
Table 4: Gel points for the combinations of multi-arms and crosslinkers used for gel 







4 2 58 
4 4 33 
8 2 38 
8 4 22 
 
The initial intention was to use conjugate addition to form all of the gels. This is the method of 
preference because it allows for an aqueous solution of gel building blocks to be injected in vivo, 
upon which gelling occurs spontaneously. However, compound 25 (PEG-4arm-G1-4Dex-8Ac) and 29 
(PEG-G2-6Dex-8Ac) were not water soluble and could therefore not be gelled through aqueous 
conjugate addition. Instead, the free radical thiol-ene addition reaction in organic solvent was 
applied for the gelling step of the dendritic categories. 
 
3.2.1   Conjugate Addition 
Aqueous solutions of PEG-Ac compounds may have a slightly acidic pH as a result from remaining 
hydrochloric acid from the acrylation reaction (unpublished results). 
 As demonstrated in Figure 31 the rate of conjugate addition is strongly pH dependent 
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Figure 31: Gelling times for conjugate addition of 20PEG-8Ac and 2nPEG-2SH at different pH, 
n =1. 
 
The pH dependence of conjugate addition originates from the acidic character of the thiol 
crosslinker, thus a maintained alkaline pH results in a greater degree of deprotonated thiols and a 




Scheme 11: Base mediated deprotonation of a thiol. 
 
To reduce the pH lowering effect of potentially remaining hydrochloric acid in the PEG-Ac 
compounds, gel building blocks were dissolved in a PBS with increased buffer capacity, namely PBS-2.  
 
The conjugate addition gels in this work reached the gel point within approximately three minutes, 
but were incubated for 45 minutes (100% relative humidity to prevent the gels from drying out) to 
allow further progress of the crosslinking. An even longer incubation time would only marginally 
increase the amount of crosslinks, since the gels get more rigid as more bonds form and the 
probability for reaction of remaining loose ends is lowered according to the Flory-Rehner theory. 
 
3.2.2   Thiol-ene Addition 
During the development of the thiol-ene gel formation protocols the relationship between 
concentration of building blocks and the amount of initiator was investigated. It was found that for a 
fixed amount of initiator a sufficiently high concentration of building blocks was required for gelling 
to occur, the reverse relation was also confirmed. 
 
3.2.2.1   Conjugate versus Thiol-ene Addition 
Conjugate and thiol-ene additions theoretically result in the same structural features, namely thio-


































B, Thiol-ene Addition 





















C, Photo Polymerisation 
rise to a mixture of weakened and non-weakened ester crosslinks as a result of a side reaction 
(homo-polymerisation; Scheme 1). As a reference for 100% homo-polymerisation gels were 
additionally formed by photo-polymerisation in the absence of a thiol crosslinker. The resulting 
degradation times, for gels made by using the three crosslinking methods, are demonstrated in 
Figure 32, as it was no longer possible to measure the drug elution when the gels were too degraded 
for decanting supernatant. Gels made by conjugate addition, thiol-ene addition and photo-
polymerisation degraded in 9, 60 and 129 days respectively. These results confirm that the close 














Figure 32: Three variations of 20PEG-8Ac (1) gels: (A) conjugate addition with 2dPEG-2SH at 
14% in PBS-2, (B) thiol-ene addition with 2dPEG-2SH at 31% in THF with 10 mol% DMPA and 
(C) photo polymerisation at 20% in 50% PBS-2 in EtOH with 1 mol% DMPA and 1000 mol% 
NVP. 
 
Regarding the photo-polymerised gels; UV irradiation of solutions of either 1 or DMPA in NVP did not 
result in gelling and a mixture of 1 and DMPA did only indicate initial gel formation after prolonged 
irradiation. Hence, DMPA is necessary for gelling to occur and NVP to accelerate the process.  
 
Although a direct comparison of the elution properties of Ra and Dex is incorrect a rough indication 
on crosslink density may be obtained by comparing the respective times for drug elution to reach a 
plateau. The plateaus were reached after 3, 2 and 17 days respectively for A, B and C (Figure 32). 
These elution profiles suggest that the photo-polymerised gels (C) have a much higher crosslink 
density than gels formed by the other two methods, which was also expected from considering the 
functionalities and nature of the involved compounds. The acrylate double bond is cleaved 
homolytically upon UV irradiation and is thus di-functional in free radical polymerisation reactions, 
such as the homo-polymerisation in thiol-ene addition. Hence, method A is an 8 + 2 arm system, 
method B is a mixture of an 8 +2 (thiol-ene route) and a 16 + 2 (homo-polymerisation route) arm 














3.3   Drug Release and Hydrogel Characterisation 
The six hydrogel categories were characterised with respect to drug elution properties and swelling 
and degradation rates of the gel scaffolds. 
 
3.3.1   Mono-functional Approaches 
The building blocks for the RaX-d4 and RaX-d2 categories were dissolved at 20% and 13%, 
respectively, during gelling. The difference in concentration was a result from the difference in 
molecular mass of the crosslinkers, because the multi-arms were always dissolved at the upper limit 
followed by addition of crosslinkers with different molecular masses; 3 (2 kDa) or 4 (10 kDa). 
 
3.3.1.1   Ra-Ac/IAE, 4-armed carrier  
Rapamycin elution from the RaX-d4 gels is shown in Figure 33. The gels, co taining either RaAc-
dPEG-3SH (7) or RaIAE-dPEG-3SH (8), displayed zero order drug release kinetics during a 15 days gel 
degradation period (Table 5). A similar constant and sustained zero order release was predicted by 
mathematical modelling, and experimentally confirmed, for degradable conjugate addition gels with 
a fluoroscopic probe covalently incorporated (DuBose et al. 2005). Following the linear release 
phase, the mathematical model predicts a burst of the remaining drug content prior to gel 
dissolution. Such trend was also observed for the release of bound drug in Figure 33, as the slopes of 
these elution curves gradually increase while the gels are degrading prior forced burst by NaOH 
treatment. The trend, however, was less pronounced than for DuBose and co-workers. Therefore the 
contribution of degradation to the release mechanism was considered to be marginal, in favour for 
hydrolysis of the hydrolytically labile drug-gel linker. 
 
The hydrolytic release of bound Ra into PBS medium produced zero order elution kinetics. The 
situation would potentially be different if the elution instead occurred into a biologically active 
medium containing enzymes and/or cells, such as serum. However, Ito et al. (2007) created a 
hydrogel, based on hyaluronic acid, with Dex covalently incorporated via a pH sensitive hydrazide 
linker in series with an ester. The gel released the drug into a cell culture medium, with or without 
10% fetal bovine serum, and there was no statistically significant difference at any time point, except 
for the 5th day. These findings support the use of PBS as elution medium for benchmarking the 
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Figure 33: Experimental data (with error bars) and calculated curve fits (dashed lines) for 
conjugate addition gels at 20% in PBS-2. Formulation (building blocks; detected amount of 
drug); Trapped (20PEG-8Ac (1) and 10dPEG-4SH (4); 69%), Bound via IAE (RaIAE-dPEG-3SH 
(8), 20PEG-8Ac (1) and 10dPEG-4SH (4), 57%) and Bound via Ac (RaAc-dPEG-3SH (7), 20PEG-
8Ac (1) and 10dPEG-4SH (4), 60%). 
 
 
Gels containing 7 reached the half amount of total drug elution (prior to forced gel degradation) after 
10.2 days, which is slightly slower than the 9.3 days it took for gels containing 8 to reach the same 
point. The two compounds are structurally very similar and the only feature that distinguishes them 
is the number of carbons between the thio-ether and ester moieties in the Ra-PEG link, namely two 
carbons (7) or one (8). However minute this difference is, it makes a distinct effect on the drug 
release kinetics since 7 is slightly less prone to hydrolysis than 8. 
 
Schoenmakers et al. have previously reported on a non-degradable hydrogel system that the 
decrease in thio-ether to ester distance for a drug-PEG conjugate from 3 to 2 carbons decreased the 
time to reach the half amount of total drug elution from approximately 10 to 3 days (Schoenmakers 
et al. 2004). Even though the drug release in both this thesis and the report from Schoenmakers et al. 
were primarily controlled by hydrolysis the difference in elution rates for the two gel formulations in 















Table 5: R2-values from curve fitting of a linear line to calculated curves based on 
experimental data, all combinations are not applicable (n.a.), and the best curve fits are 









First Order  
Rate Equation 
“Bound via Ac” n.a. n.a. n.a. 0.955 0.897 
“Bound via IAE” n.a. n.a. n.a. 0.980 0.912 
“Trapped” 0.935 0.856 0.61 0.743 0.978 
 
Trapped Ra was released faster than bound and displayed a comparable release pattern as previously 
reported for degradable PEG hydrogels (van de Wetering et al. 2005). The elution proceeded for five 
days and the data fitted significantly to the first order rate equation (Table 5; Figure 33). However, 
the use of the Hixson-Crowell or Korsmeyer-Peppas equations did not transform the experimentally 
obtained release data into linear plots, hence those equations could not be used to ascribe the 
release mechanism to degradation, diffusion or swelling. Nevertheless, by considering the swelling 
(Figure 34) and elution (Figure 33) curves it was identified that swelling equilibrium was reached 
already on the first day while the elution of trapped Ra continued until day five. This suggests that 
the release was principally controlled by diffusion and not restricted by swelling. In addition, since 
the elution did not continue during the gel degradation period, between day 5 and 13, degradation 
was not considered to contribute to the elution of trapped drug. 
 
The faster release rate of Ra from “Trapped” compared to “Bound” gels was not related to swelling 
or an altered architecture since these gels displayed a nearly identical swelling (Figure 34). The 
“Blank” gels however, always swelled slightly less than drug containing gels. It was also observed that 
“Bound” and “Trapped” gels always degraded faster than “Blank” gels, as detected by an increased 
difficulty to handle those gels. It is believed that the presence of hydrophobic drug affected the gel 
network negatively by aggravating the gel formation compared to “Blank” gels, resulting in an 
increased swelling. The difference in release rates for “Bound” and “Trapped” gels are thus 
attributed to the different release mechanisms; hydrolysis and diffusion, respectively. 
 
In Figure 33 approximately 60% of bound and 70% of trapped drug was detected. Incomplete drug 
release is commonly observed in the literature, but no general explanation has been proposed for 
either bound (Nuttelman et al. 2006; Ito et al. 2007) or trapped (Forrest et al. 2006; Kim, D. H. et al. 
2006; Lin et al. 2006; Reddy et al. 2008) drug. For the results presented in this thesis the difference in 
amounts of loaded and detected drug was believed to partly origin from experimental methodology 
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Swelling Ratio 
Bound via Ac 
Bound via IAE 
Trapped 
Blank 
 Another possible explanation is that secondary release or dissolved PEG released from 
the gels quench the signal of the drug during UV quantification (unpublished results). (Ito et al. 2007) 
















Figure 34: Conjugate addition gels at 20% in PBS-2. Formulation (building blocks); Bound via 
Ac (RaAc-dPEG-3SH (7), 20PEG-8Ac (1) and 10dPEG-4SH (4)), Bound via IAE (RaIAE-dPEG-3SH 
(8), 20PEG-8Ac (1) and 10dPEG-4SH (4)), Trapped and Blank (20PEG-8Ac (1) and 10dPEG-4SH 
(4)). 
 
The swelling of the three gel formulations reached equilibrium within a few days from where further 
swelling occurred with increasing rates as the degradation progressed (Figure 34). The same swelling 
behaviour is previously reported for degradable PEG hydrogels (van de Wetering et al. 2005). 
 
As already pointed out, the “Blank” formulations always swelled a little less and lasted a little longer 
than the “Bound” and “Trapped” formulations. A lower crosslink density of “Bound” compared to 
“Blank” gels was also confirmed by calculations of crosslink densities for selected compounds (Figure 
35). The “Blank” formulation reached equilibrium on the first day followed by a steady decrease in 
crosslink density during degradation until the end point. For all time points past equilibrium the 
“Bound” gels showed a lower crosslink density than the “Blank”. At the end point, both formulations 
had an average mesh size of ~230 Ångström, only that the “Bound” formulation arrived at the end 
point ~5 days earlier than the “Blank”, which indicates a lower crosslink density. 
A possible explanation for the greater swelling and lesser crosslink density of the 
“Bound” formulation is that the incorporated drug consumes a crosslinking site, which lowers the 
overall functionality. The resulting functionalities of “Bound” gels are; 8 Ac (multi-arm) + 4 SH 






























Bound via IAE 
Blank 
Even though the ratio of Ac and SH is stoichiometric for all gels the lowering in overall functionality 
for the “Bound” gels might contribute to a decrease in crosslink density and increase in swelling. 
 
That, however, does not explain the increased swelling of “Trapped” formulations compared to the 
“Blank”. Therefore it is suggested that the drug presence disrupts gel formation, resulting in a 















Figure 35: Conjugate addition gels at 20% in PBS-2. Formulation (building blocks); Bound via 
IAE (RaIAE-dPEG-3SH (8), 20PEG-8Ac (1) and 10dPEG-4SH (4)) and Blank (20PEG-8Ac (1) and 
10dPEG-4SH (4)). 
 
None of the journal articles reviewed during the work with this thesis compare the release of 
trapped and bound drug; hence there is no suitable comparison in the literature regarding the 
different swelling of such gel formulations. 
 
3.3.1.2   Ra-Ac/IAE, 2-armed carrier 
Several drug vehicle compositions were investigated for drug delivery in this thesis, but only the RaX-
d4 and RaX-d2 categories were tested for drug elution properties. The latter gel category was made 
of 20PEG-8VS (2) crosslinked by 2dPEG-2SH and contained either RaAc-dPEG-SH (9) or RaIAE-dPEG-
SH (10). The resulting drug elution from those gels is displayed in Figure 36. 
 
The times to reach the half amount of total drug elution were 9.7 days for gels containing 9 and 5.1 
days for gels containing 10, which again display the effect of the structural difference for drug 















































Bound via IAE 


















Figure 36: Experimental data (with error bars) and calculated curve fits (dashed lines) for 
conjugate addition gels at 13% in PBS-2. Formulation (building blocks; detected amount of 
drug); Trapped (20PEG-8VS (2) and 2dPEG-2SH; 65%), Bound via IAE (RaIAE-dPEG-SH (10), 
20PEG-8VS (2) and 2dPEG-2SH, 29%) and Bound via Ac (RaAc-dPEG-SH (9), 20PEG-8VS (2) 
and 2dPEG-2SH, 49%). 
 
The “Bound” formulation where Ra was incorporated via Ac agreed well with the zero order rate 
equation, but the elution from “Bound via IAE” gels agreed the b st with the first order rate equation 
(Table 6). This unexpected release profile may be a result from a decreased quality of gel formation, 
as indicated by a considerable increased swelling of those gels compared to the “Bound via Ac” and 
“Blank” formulations (Figure 37). Nevertheless, the release from “Bound via IAE” gels was 
significantly more controlled than release from “Trapped” gels, and the elution also showed good 
agreement with the zero order rate equation while trapped elution data was on the border to fit the 




-values from curve fitting of a linear line to calculated curves based on 
experimental data, all combinations are not applicable (n.a.), and the best curve fits are 









First Order  
Rate Equation 
“Bound via IAE” n.a. n.a. n.a. 0.966 0.989 
“Bound via Ac” n.a. n.a. n.a. 0.986 0.861 
“Trapped” 0.894 0.805 0.46 0.688 0.950 
 
The release mechanism from the “Trapped” formulation could not be established with the Hixson-
Crowell or Korsmeyer-Peppas equations, because of the poor curve fitting. Nevertheless, release of 
trapped drug continued until day 4 (Figure 36) while the swelling equilibrium was reached already on 
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Figure 37: Conjugate addition gels at 13% in PBS-2. Formulation (building blocks); Bound via 
IAE (RaIAE-dPEG-SH (10), 20PEG-8VS (2) and 2dPEG-2SH), Bound via Ac (RaAc-dPEG-SH (9), 
20PEG-8VS (2) and 2dPEG-2SH), Trapped and Blank (20PEG-8VS (2) and 2dPEG-2SH).  
 
The RaX-d4 and RaX-d2 categories were built with different carriers, crosslinkers and multi-arms for 
the following reasons; 
 Ra has low water solubility and a PEG carrier of 1.5 kDa (1.5dPEG-2SH) was just 
sufficient to render the drug soluble. Even though 3 (2 kDa) was investigated as a carrier in the RaX-
d2 category it was preferred to keep a larger margin to the 1.5 kDa limit, hence 4 (10 kDa) was used 
in the main RaX-d4 category within the mono-functional approach. Another argument for using 4 in 
favour of 3 is the higher risk of Ra saturation by di-substitution of the 2-armed carrier, resulting in a 
non-soluble conjugate and no Ac groups left for hydrogel incorporation. For the 4-armed carrier on 
the other hand, a di- or tri-substitution would not ruin its function, since such conjugates would still 
be water soluble and have at least one Ac group left for gel incorporation. 
 The carrier and crosslinker were always the same in order to make the gel 
formulations as similar as possible. Consequently, the crosslinkers were different for the RaX-d4 and 
RaX-d2 categories. 
As earlier described, during synthesis of the Ac and VS functionalised multi-arms there 
was a substantial amount of self-initiated polymerisation for the latter compound. In order to avoid 
possible homo-polymerisation of PEG-8VS during gel preparations the PEG-8Ac compound was 
preferred. 
 
3.3.1.3   RaDiIAE, no carrier 
During synthesis of RaMonoAc (5) and RaMonoIAE (6a) the di-substituted by-products were isolated 









































RaDiIAE (6b) was copolymerised into a gel without previous conjugation to 10dPEG-4SH or 2dPEG-
2SH.  
The degradation time of 12 days (Figure 38) was slightly longer than for similar gels 
reported in the literature, where the gels (15PEG-4Ac crosslinked by 3nPEG-2SH at 40%) degraded in 
8 days, even though the contrary was expected due to the nature of the respective crosslinks (Elbert 
et al. 2001). The use of Ra-2IAE as crosslinker is believed to turn the immediate proximity of the 
crosslink relatively hydrophobic, hence decreasing the rate of hydrolysis. A similar argumentation has 
previously been presented in the literature for explaining a prolonged degradation time of PEG gels 
(Schoenmakers et al. 2004). 
 
The resulting gels contained a large proportion of Ra and 17.2 mg Ra/g gel was detected, compared 
to 3.3 and 2.2 mg Ra/g gel, respectively, for the RaMonoIAE gels in the RaX-d4 and RaX-d2 
categories. A disadvantage however, is that non-PEGylated Ra is not water soluble and gelling must 
occur in a mixture of organic and aqueous solvents, thus making these gels improper for in situ 
gelling. 
The elution of bound Ra from the RaX-d4 (Figure 33) and RaDiIAE (Figure 38) 
categories revealed similar profiles for the first seven days. Thereafter the RaX-d4 gels continued the 














Figure 38: Gelling through nucleophilic substitution at 18% in MeCN and NaHCO3 (2:1). 
Formulation (building blocks; detected amount of drug); RaDiIAE (RaDiIAE (6b) and 10dPEG-
4SH (4); 47%). 
 
If the release profile of RaDiIAE gels is divided into an initial zero order release (day 1-7) followed by 























Time [Days]  
Swelling Ratio 
RaDiIAE 
al. 2005). As Figure 38 and 39 demonstrate the drastic increase in Ra release appeared 
simultaneously as the swelling started to increase. The biphasic release however, was much more 
pronounced than the results from DuBose et al. and this discrepancy is believed to origin from the 
inherent gel properties. DuBose et al. also showed that the biphasic character decreased in favour 
for zero order release when the crosslink density was increased. Therefore, the profile in Figure 38 is 
believed to have had a higher proportion of the zero order phase if the gel had a higher crosslink 












Figure 39: Gelling through nucleophilic substitution at 18% in MeCN and NaHCO3 (2:1). 
Formulation (building blocks); RaDiIAE (RaDiIAE (6b) and 10dPEG-4SH (4)). 
 
 
Due to lack of suitable control compounds (similar to 6b, but drug deficient) the “Blank” and 
“Trapped” formulations had to be omitted in this case. Normally, supernatant from the “Blank” gels 
was used as background reading during UV quantification of released drug for the corresponding 
“Trapped” and “Bound” formulations. Since no “Blank” gels were made in this experiment a mixture 
of PBS-1 and EtOH was used instead for the “Blank” supernatant. This approximation is justified by 
comparing the obtained background level (0.074 ±0.005) with the level of “Blank” RaX-d4 gels (0.070 
±0.006), which are essentially the same. 
 
The gelling of 6a and 4 was the final proof that drug-PEG conjugates actually form, because if gelling 
of RaDiIAE and PEG-4SH occurs then the reaction of RaMonoIAE and PEG-4SH also takes place, even 












































3.3.2   Dendritic Approaches 
Discussions regarding reasons for zero order release from “Bound” and first order release from 
“Trapped” formulations, difference in elution profile between bound and trapped drug, incomplete 
drug release and swelling trends of the three gel formulations as presented for the mono-functional 
approach are also valid here and will not be repeated. 
 Since these formulations are unique, there is a void in the literature of applicable 
comparisons regarding elution and swelling characteristics. 
 
3.3.2.1   First Generation, 2-armed backbone 
G1 was the only category within the dendritic approach where the compound remained water 
soluble after Dex incorporation. The solubility limit was approximately 130 mg/ml PBS-2 and 
consequently gelling at a similar concentration as for the mono-functional categories was possible. 
The G1 category was gelled by both conjugate and thiol-ene additions. 
 
3.3.2.1.1   Gelling Through Conjugate Addition 
The hydrolytically released drug from the “Bound” formulation displayed a constant zero order 
release profile during the entire elution period (Figure 40, Table 7), independently of swelling and 













Figure 40: Experimental data (with error bars) and calculated curve fits (dashed lines) for 
conjugate addition gels at 19% in PBS-2. Formulation (building blocks; detected amount of 
drug); Trapped (PEG-G1-4Ac-2Act (20) and 10nPEG-4SH; 71%) and Bound G1 (PEG-G1-4Ac-
2Dex (21) and 10nPEG-4SH; 49%). 
 
Drug incorporation using the HDC click reaction resulted in a triazole containing link between the 





























groups and is not weakened by electron withdrawing groups. Instead the next following ester is 
believed to be weakened by the triazole moiety, since this ester has a two carbon distance to 




Figure 41: Details of the drug-gel link for the dendritic approach. 
 
However, a Dex-OHPrim conjugate still has biological activity (Rebuffat et al. 2002), which was also 
confirmed by an in vitro cell assay shown later in this text. 
 
The release mechanism of trapped drug could not be established by the Hixson-Crowell and 
Korsmeyer-Peppas equations, but was considered to be primarily controlled by diffusion after 
comparing the elution and swelling curves (Figure 40 and 42). The first order rate equation, on the 
other hand, agreed well with the trapped data (Table 7). 
 
Unexpectedly, the “Trapped” gels were dissolved at day 5 while “Bound” gels were still rather intact, 












Figure 42: Conjugate addition gels at 19% in PBS-2. Formulation (building blocks); Trapped 
























































Table 7: R2-values from curve fitting of a linear line to calculated curves based on 
experimental data, all combinations are not applicable (n.a.), and the best curve fits are 
















“Bound” n.a. n.a. n.a. 0.986 0.968 
“Trapped” 0.938 0.855 0.23 0.635 0.968 
 
Thiol-ene 
“Bound” n.a. n.a. n.a. 0.986 0.925 
“Trapped” 0.795 0.773 0.08 0.534 0.758 
 
3.3.2.1.2   Gelling Through Thiol-ene Addition 
Regarding the G1 compounds gelled by thiol-ene addition; the elution of hydrolytically released drug 
followed a zero order profile between day 1 and 11, but elution data from the “Trapped” formulation 
did not agree with any of the used models and was thus considered to be of burst character (Figure 
43 and Table 7). 
 
For gelling through thiol-ene addition the general aim was to dissolve the dendritic compounds at 
high concentrations in order to keep the amount of potentially toxic initiator low and the UV 
irradiation time short. Nonetheless, to keep the concentration of G1 gels similar for the two gelling 
methods the concentration of G1 thiol-ene gels was decreased to a minimum, which resulted in the 












Figure 43: Experimental data (with error bars) and a calculated curve fit (dashed line) for 
thiol-ene addition gels at 38% in THF with 10 mol% Irgacure 2959. Formulation (building 
blocks; detected amount of drug); Trapped (PEG-G1-4Ac-2Act (20) and 10nPEG-4SH; 79%) 
































Even though the same batch of PEG-G1-4Ac-2Dex (21) was used to form gels via conjugate (Figure 
40) or thiol-ene addition (Figure 43), the bound drug in the latter case set off with a minor burst 
release. An initial burst followed by zero order release was also observed for the 4arm category and 
in some of the experiments with the G2 category (not shown). The obvious reason for a burst release 
is the presence of non-covalently bound drug diffusing from the gel immediately upon immersion. 
However, any potentially unbound drug is not believed to originate as a contamination in the 
product since the burst releases were only occasional. A possible explanation is that the drug is 
released during gel formation procedures, resulting in a small amount of drug being trapped in the 
gel matrix. Possibly the drug was cleaved off by the UV irradiation during gelling, because the initial 
burst release of bound drug was not observed in the mono-functional approach. 
 
Despite the fact that incorporation of hydrophobic drugs is expected to increase the hydrophobicity 
of the hydrogel, and consequently lower its swelling, the “Bound” gels showed an increased swelling 
compared to the other two gel formulations. Nonetheless, the three gel formulations had similar 
degradation times (Figure 44), which was interpreted as an indication that the gels have roughly the 
same crosslink density. A comparison of the collected raw data provides the information that Wg of 
“Bound” gels was approximately half the value compared to the other formulations, but Ws was 
nearly equal for the three formulations. Therefore it was believed that these “Bound” gels lost more 
solvent through evaporation during preparations, hence a lowered Wg and a higher swelling ratio. An 
alternative explanation is if the increased swelling was a result of lower crosslink density, in such case 












Figure 44: Thiol-ene addition gels at 38% in THF with 10 mol% Irgacure 2959. Formulation 
(building blocks); Bound G1 (PEG-G1-4Ac-2Dex (21) and 10nPEG-4SH), Trapped and Blank 














G1 gels crosslinked by conjugate addition degraded faster than those made by thiol-ene addition (5 
and 11 days respectively). Even though the concentrations of gel building blocks were different for 
the two gelling methods, 19 and 38% respectively, it was assumed that formation of non-weakened 
ester bonds during the thiol-ene addition prolonged the degradation time for these gels. Combining 
previous and published results strengthens this assumption. Previously shown in Figure 32, an 8 + 2 
arm system of PEG derivatives was gelled via either conjugate (at 14%) or thiol-ene (at 31%) 
additions with a resulting 7-fold difference in degradation time (8 and 59 days respectively). In 
contrast, Mason et al. and Dubose et al. describe that a doubling in concentration (25 to 50% and 10 
to 20%, respectively) only prolonged the degradation time 2-fold or by 25% for hydrolytically 
degradable gels made by photo-polymerisation of PLA-b-PEG-b-PLA-2Ac building blocks or conjugate 
addition of 20PEG-8Ac and dithiothreitol (Mason et al. 2001; DuBose et al. 2005). In light of these 
experiments it is believed that the gels made by thiol-ene addition degraded more slowly than those 
made by conjugate addition as a result of an increased bond stability, and only marginally because of 
an increased crosslink density. 
 It was also observed that the degradation time for G1 gels formed by conjugate 
addition was shorter than for the RaX-d4 and RaX-d2 gels, as summarised in Table 8. By considering 
the functionality of gel building blocks for gels at similar concentrations a lucid picture of the 
resulting degradation rates is developed. 
 
Table 8: A comparison of blank conjugate addition gels regarding composition and resulting 
properties. 





RaX-d4 8 + 4 20% 15 
RaX-d2 8 + 2 14% 9 
G1 4 + 4 19% 4 
 
The category with the most crosslinking sites of the multi-arm and crosslinker combined (RaX-d4) 
produced the most durable gels and the G1 category, with the least combined number of sites, 
degraded the fastest. Despite that the RaX-d4 and G1 categories were gelled at a slightly higher 
concentration than the RaX-d2 category, the latter gels followed the trend and degraded faster than 
RaX-d4 but slower than the G1 category. Hence, the fewer crosslinking sites for the G1 gels, 











































3.3.2.2   First Generation, 4-armed backbone 
After a minor burst the covalently bound drug was released in a zero order mode between day 1 and 
27 (Figure 45, Table 9). In contrast, the entire elution of trapped drug was released with a burst 
during the first few days. 
 
Table 9: R2-values from curve fitting of a linear line to calculated curves based on 
experimental data, all combinations are not applicable (n.a.), and the best curve fits are 









First Order  
Rate Equation 
“Bound” n.a. n.a. n.a. 0.998 0.854 













Figure 45: Experimental data (with error bars) and a calculated curve fit (dashed line) for 
thiol-ene addition gels at 69% in THF with 5 mol% Irgacure 2959. Formulation (building 
blocks; detected amount of drug); Trapped (PEG-4arm-G1-8Ac-4Act (24) and 2dPEG-2SH; 
67%) and Bound 4arm (PEG-4arm-G1-8Ac-4Dex (25) and 2dPEG-2SH; 87%). 
 
The 4arm compounds were dissolved at their upper solubility limit at 400 mg/ml THF and 
consequently the amount of initiator needed for gelling could be kept low (5 mol%). 
 
Each arm of the compounds in the G1 and 4arm categories is structurally identical, but the different 
number of arms resulted in either 4 or 8 crosslinking sites for the compounds in the respective 
category and gave the gels dissimilar properties, as presented here for the thiol-ene gels. 
 
As expected from considering gel parameters, gels in the 4arm category degraded slower than the 
corresponding G1 thiol-ene gels (27 and 11 days respectively). There are two reasons for this; firstly, 






























category (38%) and secondly, the 4arm gels were made in an 8 + 2 arm system while G1 gels were of 
a 4 + 4 arm system. Both reasons result in a higher crosslink density for the 4arm gels and, hence, 
slower degradation. 
 A consequence of an increased number of crosslinks is a denser gel, which swells less. 
This was confirmed by comparing the swelling ratios of “Blank” formulations at equilibrium for the 
G1 (Figure 44) and 4arm (Figure 46) categories, which were 10 and 4 respectively. 
 These two categories had different drug loading capacities; 2 and 4 Dex molecules per 
carrier for the G1 and 4arm category respectively. The different loadings were clearly mirrored by the 
amount of detected drug released from the two categories; 29 mg Dex/g gel (Figure 43) and 65 mg 












Figure 46: Thiol-ene addition gels at 69% in THF with 5 mol% Irgacure 2959. Formulation 
(building blocks); Bound 4arm (PEG-4arm-G1-8Ac-4Dex (25) and 2dPEG-2SH), Trapped and 
Blank (PEG-4arm-G1-8Ac-4Act (24) and 2dPEG-2SH). 
 
Compound 25 was reprecipitated prior to the crosslink density experiment in order to remove 
impurities from spontaneous crosslinking. As already mentioned, the compounds with high Dex 
loading (4arm and G2 categories) were difficult to precipitate in diethyl ether and at this occasion the 
product came out poorly with reduced quality of gel formation as a result, hence mesh size 












































3.3.2.3   Second Generation, 2-armed Backbone 
The “Bound” formulation in the G2 category displayed a zero order drug release, until the degrading 
gels were treated with alkali to force the last amount of Dex to release with a burst (Table 10, Figure 
47). 
 
Table 10: R2-values from curve fitting of a linear line to calculated curves based on 
experimental data, all combinations are not applicable (n.a.), and the best curve fits are 









First Order  
Rate Equation 
“Bound” n.a. n.a. n.a. 0.979 0.945 
“Trapped” 0.880 0.844 0.38 0.599 0.950 
 
The G2 compounds were less soluble than the 4arm compounds and were dissolved at 300 mg/ml 












Figure 47: Experimental data (with error bars) and calculated curve fits (dashed lines) for 
thiol-ene addition gels at 50% in THF with 5 mol% Irgacure 2959. Formulation (building 
blocks; detected amount of drug); Trapped (PEG-G2-8Ac-6Act (28) and 2dPEG-2SH; 77%) and 
Bound G2 (PEG-G2-8Ac-6Dex (29) and 2dPEG-2SH; 37%). 
 
Although a lower total amount of Dex was detected (51 mg/g gel) compared to the “Bound” 
formulation in the 4arm category (65 mg/g gel; Figure 45), the G2 gels had the highest drug loading 
density of the three dendritic categories developed in this work, namely 138 mg Dex/g gel. The 
corresponding values for the G1 and 4arm categories are 48 and 75 mg Dex/g gel, respectively. The 































The release of trapped drug followed a first order profile, but the elution mechanism could not be 
established by the Hixson-Crowell and Korsmeyer-Peppas equations (Table 10). Nonetheless, by 
comparing the elution and swelling curves, the elution was considered to be controlled by diffusion 












Figure 48: Thiol-ene addition gels at 50% in THF with 5 mol% Irgacure 2959. Formulation 
(building blocks); Blank and Trapped (PEG-G2-8Ac-6Act (28) and 2dPEG-2SH) and Bound G2 
(PEG-G2-8Ac-6Dex (29) and 2dPEG-2SH). 
 
Once again the close relationship between crosslink density, swelling and degradation is 
demonstrated experimentally. By comparing the “Blank” formulations of respective category it is 
found that the 4arm gels, made at a concentration of 69% with an equilibrium swelling of 4, 
degraded in 27 days (Figure 46) while G2 gels, which were made at a lower concentration (50%) had 
a higher equilibrium swelling (8) and shorter degradation period (15 days; Figure 48). Both 
formulations were of an 8 + 2 arm system. 
 
The “Bound” formulation swelled somewhat less than the “Blank” and “Trapped” formulations 
(Figure 48) and the calculated relative mesh size was much lower than for the “Blank” formulation 
(Figure 49). Although both parameters indicate a higher crosslink density for the “Bound” 
formulation all three formulations degraded within a similar period of time and, hence, their 
crosslink densities were probably similar. 
 This assumption is supported by regarding the water solubility of the building blocks. 
Compound 29 is not water soluble and consequently gels build from compound 29 are less 
hydrophilic then gels build from the water soluble compound 28. Therefore the “Bound G2” gels 
have a disfavoured interaction with water leading to a lower degree of swelling than for the “Blank” 

































Relative Crosslink Density 
Blank  
Bound G2 
to  ∝ swelling-1. Consequently, the lower degree of swelling for the “Bound” formulation, caused by 













Figure 49: Thiol-ene addition gels at 50% in THF with 5 mol% Irgacure 2959 (n =2). 
Formulation (building blocks); Blank (PEG-G2-8Ac-6Act (28) and 2dPEG-2SH) and Bound G2 
(PEG-G2-8Ac-6Dex (29) and 2dPEG-2SH). 
 
3.3.3   Summary 
In Table 11 gelling parameters for the “Bound” formulation of each category and the resulting gel 
properties are summarised.  
 


































2 49 2.3 17 
RaIAE-d2 4 29 2.2 19 
RaDiIAE 18 2 10dPEG-4SH 2 47 17 11 
 
G1 (Conjugate addition) 19 
4 10nPEG-4SH 
5 49 6 5 
G1 (Thiol-ene addition) 38 18 60 29 11 
4arm 69 8 2dPEG-2SH 4 87 65 27 
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Rapamycin Standard Curve 
3.4   Reporter Assays 
Supernatant from the “Blank”, “Trapped” and “Bound” gel formulations of the mono-functional and 
dendritic approaches were tested on appropriate cell types in order to verify maintained biological 
activity of the released drugs. 
 
3.4.1   Rapamycin 
In Figure 50 the reduction of cell proliferation after treatment with known amounts of Ra is shown. 
The reduction was smaller than expected and the proliferation was only reduced to 77% for the 









Figure 50: Influence of rapamycin on smooth muscle cell proliferation, n =3. 
 
In the literature however, a treatment of 100 μg Ra/l cell medium reduced the proliferation to 
approximately 65-70% (Reddy et al. 2008; Yallapu et al. 2008). The results in the literature were 
obtained by UV quantification of a formazan dye formed by adding an assay reagent to cell samples. 
The results in this work were obtained by measuring the luminescence from adenosine 5-
triphosphate (ATP) dependent luciferase activity obtained by another cell assay. Since the outcome 
from both assays is proportional to the number of living cells it was assumed that the measured 
reduction in cell proliferation should be similar. 
 
The discrepancy is believed to originate from the recommended protocol (10 min incubation time in 
Troom with only initial shaking) where the incubation of cells and cell viability reagent is not sufficient 
for thorough cell lyses to occur. For samples with not fully lysed cells only a partial amount of the 
present cells are measured and the results are inaccurate. Therefore the experiment was repeated, 
and by using a modified protocol the monitored reduction of proliferation was more pronounced 

































The Ra concentration in the prepared cell treatments was within the linear range (63 -2000 µg /l) of 
the standard curve (Table 12). 
 
Table 12: UV quantified concentrations of eluted rapamycin from the RaIAE-d4 category. 













The resulting cell growth from treating cells with Ra containing supernatants is shown in Figure 51. 
Treatment with supernatant from the “Blank” gels, to start with, resulted in a reduced proliferation 
at both time points (~80%). This is however considered to be within the experimental error since the 
reduction for cell treatment with low amounts of Ra in the standard curve (Figure 50, right hand side 












Figure 51: Cell treatment with supernatant from the three RaIAE-d4 gel formulations. 
 
Unexpectedly though, the resulting cell growth from treatment with supernatant from the “Bound” 
gels were in the same range as the “Blank” treatment. The conclusion would have been that the 
eluted Ra was inactive if not for the results of the “Trapped” treatment. The eluted Ra from these 
gels also revealed low or no activity towards the cells even though the “Trapped” Ra was the very 
same unmodified drug that was used for the standard curve where it effectively reduced 






























Concentration of Dex [M] 
Dexamethasone Standard Curve 
eluted drugs is that the former treatment was made up in MeOH and diluted with PBS-1 and media 
while the drug in the latter case was eluted in PBS-1 and diluted with MeOH and media. Thus, it was 
assumed that there is an, as yet undefined, parameter in the gel supernatants that inhibits the effect 
of Ra or impedes the assay. To uncover the particular situation further investigation is required. 
 
3.4.2   Dexamethasone 
Figure 52 shows how Dex, in a dose dependent manner, induced luciferase expression as measured 
by a standard luciferase assay. Both the lowest (10-8 M) and highest (10-6 M) concentrations for linear 












Figure 52: Dexamethasone induced luciferase expression, n =3. 
 
Supernatant from the G1 conjugate addition gel formulations were tested for maintained biological 
activity (Figure 53). The degradation products from the “Blank” gels did not increase the luciferase 
expression compared to untreated cells. Dex containing supernatant from the “Trapped” formulation 
was active, but the activity was decreasing and was all but absent on day 5. “Bound” gels on the 
other hand eluted Dex at a relatively constant rate, which was also reflected by the measured activity 
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Figure 53: Cell treatment with supernatant from the G1 conjugate addition gel formulations 
(n =3). 
 
By considering Figure 54 it is evident that supernatant from “Bound” gels, in case of both 4arm and 
G2, is active at a nearly constant level from the first days of drug elution all the way to gel 









Figure 54: Cell treatment with supernatant from the 4arm and G2 categories, respectively (n 
=3). 
 
To avoid any potentially negative effect on cells from THF the supernatant from day 1 was not tested 
for the 4arm and G2 categories. Supernatant was instead tested for day two and also for the last day 
of drug elution, prior to alkali treatment, for the “Bound” formulations, while “Trapped” supernatant 
was only tested for the last day. 
 
The activity measurement of supernatant from “Blank” 4arm and G2 gels was omitted. Since all 
dendritic categories were built from the same building blocks, only with different geometries, it was 














released from the 4arm and G2 categories. Therefore supernatant from “Blank” G1 gels is also 
representative for the 4arm and G2 categories. 
 
The primary hydroxyl group of Dex was used for the drug conjugation in this work. Even though this 
hydroxyl group interacts with the glucocorticoid receptor (Bledsoe et al. 2002) it does not contribute 
to the biological activity of Dex (Gruneich et al. 2004) and is therefore a favourable site for 
conjugation. As previously mentioned, Dex is believed to be released while still attached to a few 
methylene groups followed by a triazole. However, (Rebuffat et al. 2002) confirmed by an in vitro 
competition binding assay that Dex conjugated at the primary hydroxyl still demonstrates affinity to a 
rat glucocorticoid receptor. 
 
The amount of Dex in the supernatants either measured by UV or calculated from the fold 
inductions, were in the same range (Table 13). 
 
Table 13: Comparison of Dex concentrations in supernatant obtained by either UV-
measurements (Sen et al.) or fold inductions (F.I.). Concentrations are given in mg/l 
supernatant. For fold inductions too high for the linear rang  of the standard curve the 
corresponding concentration is marked by a dash. 
 
 
G1 Conjugate Addition 4arm G2 
Day 1 Day 2 Day 5 Day 2 Day 27 Day 2 Day 16 
“Bound” 
UV 8 11 5 18 8 7 6 
F.I. 47 33 26 51 33 29 26 
 
“Trapped” 
UV 75 31 0 74 0 79 1 
F.I. - - 0 - 0 - 0 
 
Concentrations in gel supernatant exceeding the aqueous solubility limit of Dex are attributed to the 
secondary release mechanism where Dex is released while still linked to a piece of PEG keeping the 





























4   CONCLUSIONS 
 
he results in this thesis confirm the hypothesis that zero order release kinetics is obtainable 
from injectable and degradable hydrogels by covalently attaching the drug to the hydrogel 
matrices. 
 
Regarding the specific aims stated in the introduction (chapter 1.5), each corresponding conclusion is 
listed in the following text. 
 
Building blocks: 
Multi-arms, crosslinkers, drug derivatives and drug conjugates were successfully synthesised with 
moderate to excellent yields and the product structures were confirmed by appropriate analytical 
methods. The drug loading density was varied by design of the carriers and was 1 Ra per carrier for 
the mono-functional approach and 2, 4 or 6 Dex molecules per carrier for the dendritic approach. 
However, the loading of 4 or 6 Dex molecules per carrier were too high to maintain water solubility 
of the carrier. 
 
Hydrogels: 
Conjugate and thiol-ene addition reactions were investigated for gelling of the building blocks. For 
conjugate addition the gelling rate was shown to be pH dependent. Conditions for thiol-ene addition 
were optimised by tuning the concentration of building blocks, amount of initiator and irradiation 
time. Differences between the gelling methods were investigated and assessed to mainly consist of a 
large proportion of homo-polymerisation for the thiol-ene addition, which results in slower gel 
degradation. 
Gel degradation was tuned by using multi-arms modified with either Ac or VS groups 
crosslinked by either dPEG-SH or nPEG-SH, by varying the number of crosslinking sites and by using 
different crosslinking methods. The gels made in this work showed a range of degradation times 
between 5 and 129 days. 
 
Drug elution: 
The elution profiles of covalently incorporated drugs were of zero order for both the mono-
functional and dendritic approaches and were sustained for 5-28 days depending on the individual 
gel formulation. Additionally, by incorporating Ra via either an IAE or Ac linker the elution rate was 















elution from 9.3 to 10.2 days and from 5.1 to 9.7 days, for the RaX-d4 and RaX-d2 formulations 
respectively. Dex released from the dendritic gels showed a preserved biological activity which was 
roughly constant during the entire elution period for the “Bound” formulations but declining for the 
“Trapped” formulations, which corresponds well with the drug elution profiles obtained by UV 
measurements. 
The release mechanism of “Trapped” drugs could not be described by the Hixson-
Crowell or Korsmeyer-Peppas equations, but by comparing elution and swelling curves the release 
was considered to be controlled by diffusion. The “Trapped” release followed either first order or 
burst release kinetics 
 
Thus, the hydrogel concepts developed in this work are promising tools for controlled drug delivery 
in general and local delivery of Ra and Dex with the potential to ameliorate cardiovascular healing in 
particular. Additionally, from a rigorous search in the present literature it is concluded that the work 
in this thesis is a substantial and significant contribution to the field of controlled drug delivery in 
terms of (A) slow release of Ra obtained by covalent incorporation into hydrogels, (B) the use of 
unique PEG-based dendrimers to incorporate Dex into a hydrogel and (C) zero order sustained 
release of Dex at physiological pH. 
 
4.1   Complementary Work 
The content in this thesis is a strong foundation from which further research has the potential to be 
developed, such work might for instance include the following topics; 
 
 To develop hydrogels with a slower degradation rate by combining 20PEG-8VS and 10dPEG-
4SH or by tuning the weakening of ester crosslinks with other functional groups than thio-
ethers. This will prevent the interruption of drug elution by gel dissociation. 
 To further develop these drug delivery concepts by combining the simple synthesis of the 
mono-functional approach with the multivalency and orthogonal properties of the dendritic 
approach. 
 To continue the evaluation of the drug eluting and gel degradation properties in a biologically 
active medium, such as fetal bovine serum. 
 To evaluate the developed hydrogels in vivo, initially for inflammatory response, and if 
biocompatibility is good, also for post MI amelioration and graft patency. 















5   ACKNOWLEDGEMENTS 
 
any persons contributed to the development and completion of this thesis and I would like 
to show these persons my sincere gratitude. 
 
During dull times when failed experiments and unsolved problems darkened my mood there was 
always a smile and cheerful encouragement to receive from dear Irina My, which to a great part 
inspired me to continue. 
 
General acknowledgement is directed to Onderneming and my neighbors for making Cape Town my 
home, to Welmoed, Vergelegen, Seidelberg and all the other wine estates around Cape Town for the 
merry times provided, to Devil’s Peak for its beauty and the ocean for the adventures. 
 
UCT-side 
Most of all I want to put all light on my excellent supervisor Dr. Deon Bezuidenhout who in an 
encouraging and supportive manner guided me through this work. Many thanks are directed to Prof. 
Peter Zilla for accepting me as a PhD student in the Cardiovascular Research Unit and finding 
financial aid for a majority of the project. The many hours in the lab were brightened by good 
company of Anel Oosthuysen who is sincerely accredited for valuable input on method development 
and for daily giving a helping hand. Mona Bracher is greatly thanked for help with preparing cells, 
planning and interpreting cell experiments. Dr. Karen Kadner is acknowledged for assistance on 
determining pH dependence of conjugate addition. 
 
Late Prof. Wolf Brandt (Dept. of Molecular & Cellular Biology) and Dr. Marietjie Stander (University of 
Stellenbosch, Central Analytical Facilities) were both great assets for access, development and 
interpretation of several analysis methods. Dr. Gareth Arnott (Stellenbosch University, Dept. 




The knowledge and experience accumulated by Yvonne Hed were essential to develop the dendritic 
approach and she was also a major support and a good friend during long lab hours. Yvonne was 
involved in several of the synthesis; particularly she produced the azide anhydride, purified 















sincere gratefulness for finding complementary funds to finish the project in Cape Town and for 
welcoming me to his lab at KTH. Dr. Michael Malkoch is thanked for sharing his dendritic chemistry, 
valuable input on planning the dendritic approach and sharing his experience. Thanks are directed to 
Kim Öberg for aiding my project at KTH and preparing compounds for subcutaneous implants at UCT 
and to Prof. Mats Johansson for guidance in the field of thiol-ene chemistry.  
 
Apart from the respective university institutions economic aid was also obtained from my parents 
















6   APPENDIX I; ATORVASTATIN 
 
n additional drug considered for gel incorporation in this PhD project was Atorvastatin (At), a 
member of the statin class of drugs. This drug was chosen on behalf of its documented ability 
to balance cholesterol levels (Schachter 2004), reduce atherosclerosis (Blumenthal 2000) and inhibit 
tumour cell growth (Bellosta et al. 2000). In addition, statins have the ability to reduce plasma levels 
of C-reactive protein, a general marker for systemic inflammation and a predictor of cardiovascular 
events (Ridker et al. 2002). In a study by Ridker et al. the statin treatment of apparently healthy 
patients with normal cholesterol levels but elevated levels of C-reactive protein reduced the 
occurrence of cardiovascular events by 50% compared to the placebo group (Ridker et al. 2008). 
The collective benefits of statin treatment on cardiovascular diseases strengthened 
the motivation for developing a platform for controlled delivery of At. 
 
Atorvastatin was successfully isolated from commercial tablets sold for oral delivery and was 
















Figure 55: ESI-MS of isolated atorvastatin. 
 
However, it was observed in some cases that the compound underwent spontaneous ring-closing 
during handling as detected by loss of H2O in the MS spectra (Scheme 12). This was not considered a 
major problem since the ring-closed derivative was assumed to ring-open again in contact with 
aqueous solutions, such as blood. But, in order to maximise the amount of ring-opened At during 
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Scheme 12: Reversible ring-closing of atorvastatin. 
 
The isolated drug was further acrylated for subsequent PEGylation, but the acrylation reaction 
however, was quenched by presence of water and therefore required the use of dry solvents which 
resulted in acrylation of both the ring-closed and ring-opened derivatives. In addition, the ring-











Scheme 13: Acrylation of atorvastatin results in a mixture of three compounds, R represents 
the main body of the drug. 
 
At this stage the PEGylation protocol was not fully developed because the product degradation 
during analysis was not yet identified. Therefore this project was put on hold in favour of 
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